Choroid plexus organoids and methods for production thereof

Choroid plexus organoids are created using WNT and BMP pathway activators to replicate the choroid plexus's CSF secretion and barrier functions, addressing the lack of functional models and enabling drug permeability studies.

JP2024169431APending Publication Date: 2024-12-05UNITED KINGDOM RESEARCH AND INNOVATION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024137752
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-01-23
Filing Date
2024-08-19
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current models of the choroid plexus lack the complexity and functionality to replicate its in vivo structure and function, particularly in terms of secreting cerebrospinal fluid (CSF) and acting as a selective barrier, hindering understanding of drug permeability across the blood-CSF barrier.

Method used

A protocol is established to create choroid plexus organoids using a combination of signaling molecules, specifically WNT and BMP pathway activators, which results in organoids with a tight epithelial barrier and the ability to secrete CSF-like fluid, characterized by the presence of markers such as TTR, MRP1, Aqp1, and ZO1, and resembling human fetal CSF.

Benefits of technology

The choroid plexus organoids recapitulate the fundamental functions of the choroid plexus, including CSF secretion and barrier formation, providing a reliable model for studying CSF production and drug permeation into the human brain.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169431000001_ABST
    Figure 2024169431000001_ABST
Patent Text Reader

Abstract

To provide choroid plexus organoids and methods for production thereof.SOLUTION: The present invention provides methods and materials relating to cultured choroid plexus organoids, comprising: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by an epithelium, plus other authentic features and markers.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to choroid plexus organoid, in particular choroid plexus organoid that comprises tight epithelial barrier and has the ability to produce cerebrospinal fluid-like fluid.The present invention also relates to a method for producing choroid plexus organoid. [Background technology]

[0002] 2. Background of the Invention The choroid plexus is a highly conserved and still poorly studied secretory tissue in the brain that, in humans, grows in proportion to brain size and serves several important functions in the brain, including formation of a protective epithelial barrier and secretion of cerebrospinal fluid (CSF) (1).

[0003] Anatomically, the choroid plexus is localized in the lateral, third, and fourth ventricles, occurring in their respective lumen. The mature choroid plexus consists of a simple cuboidal epithelium surrounding a core of mesenchymal-derived stromal tissue and fenestrated capillaries. The epithelial cells are tightly connected by tight junctions and are highly polarized, with an apical brush border facing the ventricular lumen and a basal surface facing the interstitium.

[0004] The highly polarized glandular epithelium of the choroid plexus serves several important functions in the brain, including formation of a protective epithelial barrier and secretion of CSF.

[0005] CSF is important for its protective role in maintaining physiological levels of nutrients in the brain, transporting signaling molecules and growth factors, and regulating intracranial pressure. CSF is a clear, colorless liquid that circulates through the ventricles and subarachnoid space and is then partially reabsorbed into the blood circulation through the arachnoid granulations (2-4).

[0006] CSF is produced by active secretion from the choroid plexus epithelial cells, which maximize the number of transporters and pumps in their apical brush border, and from blood filtration, which is conferred by the presence of tight junctions within the epithelial cells. The choroid plexus plays a key role in maintaining the rate of CSF production and resorption. Disturbance of this balance leads to pathologies such as hydrocephalus.

[0007] CSF production involves several mechanisms. First, Na+ is released from the apical side of choroid plexus epithelial cells. + -K + The ATPase pump and cytosolic carbonic anhydrase pump primarily transport Na into the ventricular lumen. + This osmotic force drives the transcellular influx of water through aquaporin channels. Second, ATP-binding cassette (ABC) proteins and solute carrier transporters (SLCs) allow the exchange of amino acids, nucleosides, and small peptides that require and do not require ATP hydrolysis, respectively. Choroid plexus epithelial cells also express efflux transporters such as MRP1 and MRP4. These pumps regulate the clearance of metabolic products and prevent the entry of drugs and toxic compounds, thus reducing their availability in the CSF. Third, the secretory system of choroid plexus epithelial cells is highly specialized and extensive, allowing the secretion of more complex proteins and hormones. For example, transthyretin (TTR), a carrier of thyroid hormone and retinol, is the most abundant protein synthesized and secreted by the choroid plexus (Li, X. and Buxbaum, JN (2011) Mol. Neurodegener. 6: 1-17;Richardson, SJ et al. (2015) Front. Neurosci. 9: 1-8;Johnson, BA et al. (2018) Fluids Barriers CNS 15: 22). TTR-mediated delivery of thyroid hormone to the CSF may play a role in regulating brain development. appears to play an important role in

[0008] The tightly sealed epithelium of the choroid plexus is also known as the blood-CSF barrier (B-CSF-B). Similar to the blood-brain barrier (BBB), B-CSF-B prevents toxic substances or signals in the circulation from reaching the brain. However, in contrast to the BBB, B-CSF-B is formed by a single cell type, the choroid plexus epithelial cells, which face the CSF rather than directly the brain parenchyma (5, 6). However, because CSF can freely enter and leave the brain, transport of molecules through the B-CSF-B is an alternative route to the brain.

[0009] Little is known about the development of the choroid plexus in humans. It develops through a series of stages, from pseudostratified epithelium to columnar, and then, in the final stage, highly folded cuboidal epithelium with microvilli and basally localized nuclei. Around the seventh week of gestation, in the dorsal telencephalon, a local BMP signaling gradient drives the development of the choroid plexus from the neuroepithelium, which begins to elongate towards the ventricular lumen. By setting a local threshold, BMP-secretory signals gradually specify the choroid plexus epithelium and the adjacent hemispheric cortex, the wingless-related (WNT) signaling center from which the hippocampal primordium develops.

[0010] Studies of choroid plexus patterning have been conducted in vitro. Over the past decade, significant advances in 3D culture systems, such as cerebral organoids, have enabled fundamental discoveries in human developmental biology (7–12).

[0011] However, induced choroid plexus cells generated to date have never been shown to exhibit the same structural complexity as the choroid plexus in vivo, nor have they been shown to be functional in producing CSF. Summary of the Invention [Problem to be solved by the invention]

[0012] Therefore, there is still a great need in the art to construct a functional model of choroid plexus.The choroid plexus is an important entry point of drugs into CNS.However, little is known about the regulation and permeability of B-CSF-B and how it can be used as a tool to improve the availability of certain drugs in brain.In this regard, the study of the functional model of choroid plexus can aid in understanding, especially when testing drug candidates for their ability to pass through B-CSF-B and / or BBB. [Means for solving the problem]

[0013] Summary of the Invention The inventors have established a protocol to generate choroid plexus organoids using a combination of signaling molecules.

[0014] The organoids (hereinafter referred to as "ChP organoids") have a selective epithelial barrier that secretes a CSF-like fluid in a self-contained compartment that closely resembles the CSF of the ventricles. Characterization of ChP organoids by single-cell RNA sequencing reveals the presence of epithelial and interstitial ChP populations. Proteomic analysis of organoid CSF-like fluid reveals human-specific and developmental factors as well as disease-related biomarkers. Finally, we use NMR to show that this in vitro barrier exhibits the same selectivity for small molecules as its in vivo counterpart and that ChP-CSF organoids can predict the CNS permeability of novel compounds.

[0015] Thus, the organoids provided by our protocol reproduce the fundamental functions of the choroid plexus, namely secretion and the formation of a tight epithelial barrier. We demonstrate that the organoids provided by our protocol have characteristics very similar to those of cerebrospinal fluid (CSF). We have determined that choroid plexus epithelium containing polarized cells that actively secrete a secretory fluid with a high degree of potency can be reliably and reproducibly generated within organoids.

[0016] Furthermore, using histological and electron microscopy (EM) analysis, the inventors discovered the presence of choroid plexus-specific water channels and transporters localized to the apical brush border of choroid plexus organoid epithelium. This tissue was found to exhibit tight junctions forming an epithelial barrier, and the inventors observed the formation of large fluid-filled cysts protruding from the organoids, the contents of which were highly similar to human fetal CSF when analyzed by mass spectrometry.

[0017] The present invention provides tools to study, for example, choroid plexus function, CSF production and the permeability of compounds, peptides and serum-derived proteins through the CSF into the human brain.

[0018] Thus, in one aspect, the invention provides choroid plexus organoids comprising: (a) epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by epithelium.

[0019] In some embodiments, choroid plexus organoid comprises the epithelium that comprises tight epithelial barrier.In some embodiments, choroid plexus organoid comprises one or more cysts that are surrounded by epithelium.In a preferred embodiment, choroid plexus organoid comprises the epithelium that comprises tight epithelial barrier and one or more cysts that are surrounded by said epithelium.

[0020] In a preferred embodiment, the epithelium is cuboidal epithelium.

[0021] In some embodiments, the choroid plexus organoids further comprise (c) a stromal cell population.

[0022] In some embodiments, the choroid plexus organoids have a lateral ventricular identity.

[0023] In a preferred embodiment, the choroid plexus organoids are LUM+, DCN+ and DLK1+.

[0024] In some embodiments, choroid plexus organoid is TTR+, MRP1+, Aqp1+ and / or ZO1+.In preferred embodiments, choroid plexus organoid is TTR+, MRP1+, Aqp1+ and ZO1+.

[0025] In other embodiments, choroid plexus organoid is TTR+, MRP1+, MRP4+, Aqp1+ and / or ZO1+.In other embodiments, choroid plexus organoid is TTR+, MRP1+, MRP4+, Aqp1+ and ZO1+.

[0026] In some embodiments, choroid plexus organoid comprises at least 50% TTR+ tissue.In some embodiments, choroid plexus organoid comprises at least 60% TTR+ tissue.In some embodiments, choroid plexus organoid comprises at least 70% TTR+ tissue.In some embodiments, choroid plexus organoid comprises at least 80% TTR+ tissue.In some embodiments, choroid plexus organoid comprises at least 90% TTR+ tissue.

[0027] In some embodiments, the epithelium is TTR+, MRP1+, Aqp1+ and / or ZO1+. In preferred embodiments, the epithelium is TTR+, MRP1+, Aqp1+ and ZO1+.

[0028] In some embodiments, the epithelium is MRP4+.

[0029] In some embodiments, TTR is enriched on the apical side of the epithelium. In some embodiments, Aqp1 is accumulated on the apical side of the epithelium.In some embodiments, ZO1 is accumulated on the apical side of the epithelium.

[0030] In some embodiments, TTR and Aqp1 are accumulated on the apical side of the epithelium.In some embodiments, TTR, Aqp1 and ZO1 are accumulated on the apical side of the epithelium.

[0031] In some embodiments, MRP1 is accumulated on the apical and basal sides of the epithelium.

[0032] In some embodiments, MRP4 is accumulated on the apical and basal sides of the epithelium.

[0033] For example, enrichment of a marker in a particular region of a cell can mean that the marker is more abundant in that region compared to other regions (e.g., all other regions). The marker can be substantially absent from other regions (e.g., all other regions).

[0034] In some embodiments, the choroid plexus organoids are FOXG1-.

[0035] In some embodiments, the epithelium comprises apical microvilli.

[0036] In some embodiments, the epithelium comprises a centrally basally located nucleus.

[0037] In some embodiments, the epithelium has apical-basal polarity.

[0038] In some embodiments, the epithelium is polarized and Aqp1 and ZO1 are expressed on the luminal side of the epithelium.

[0039] In some embodiments, LAT-1 is expressed on the apical side of the epithelium.

[0040] In some embodiments, epithelium accumulates certain transporters involved in nutrient transport, such as SLC23A2 (vitamin C) and / or SLC46A2 (folate).In some embodiments, choroid plexus organoid has the ability to secrete the liquid that contains one or more proteins selected from the group consisting of transthyretin (TTR), clusterin (CLU), apolipoprotein E (APOE), apolipoprotein A4 (APOA4) and lumican (LUM).

[0041] In some embodiments, the liquid comprises a phospholipid transfer protein (PLTP).

[0042] In some embodiments, the liquid comprises alpha-fetoprotein (AFP).

[0043] In some embodiments, choroid plexus organoids have the ability to secrete cerebrospinal fluid (CSF)-like fluid.

[0044] In some embodiments, the choroid plexus organoids have the ability to secrete cerebrospinal fluid (CSF).

[0045] In a preferred embodiment, the cyst comprises fluid. In a preferred embodiment, the fluid comprises transthyretin (TTR), clusterin (CLU), apolipoprotein E (A In some embodiments, the fluid comprises one or more proteins selected from the group consisting of apolipoprotein A4 (APOA4), lumican (LUM), and apolipoprotein E1 (APEA1). In some embodiments, the fluid is CSF.

[0046] In some embodiments, the liquid comprises alpha-fetoprotein (AFP).

[0047] In some embodiments, the fluid comprises developmental-specific CSF proteins, such as insulin-like growth factor 2 (IGF2), IGFBP7, and / or follistatin-like protein 1 (FSTL1).

[0048] In some embodiments, choroid plexus organoid comprises less than 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% (v / v) of forebrain neural tissue.In some embodiments, choroid plexus organoid is substantially free of forebrain neural tissue.

[0049] In some embodiments, choroid plexus organoid comprises less than 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% (v / v) FOXG1+ tissue.In some embodiments, choroid plexus organoid is substantially free of FOXG1+ tissue.

[0050] In some embodiments, the choroid plexus organoids comprise an extracellular matrix (ECM).

[0051] In some embodiments, choroid plexus organoids have primary cilia, including microvilli on the apical surface, tight junctions between cells, multivesicular bodies, and extracellular vesicles.

[0052] In some embodiments, the choroid plexus organoids are human or mouse organoids, preferably human organoids.

[0053] In some embodiments, choroid plexus organoids are obtainable by the methods of the present invention.

[0054] In some embodiments, choroid plexus organoids are generated from stem cells, optionally embryonic stem cells or induced pluripotent stem cells.

[0055] In another aspect, the present invention provides the use of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator to generate choroid plexus organoids, wherein the choroid plexus organoids comprise: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by the epithelium.

[0056] The use of Bmp4 and / or CHIR has been reported previously (see (15) and (16)), but those prior publications have not yielded ChP organoids with the authentic characteristics demonstrated herein.

[0057] In another aspect, the present invention provides a method for producing choroid plexus organoids, comprising contacting a neuroepithelial cell population with a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator, wherein the choroid plexus organoids comprise: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by the epithelium.

[0058] The method may be performed with or without a fibrous microscaffold, although the absence of a microscaffold may be preferred.

[0059] In another aspect, the present invention provides a method for producing choroid plexus organoids, comprising: producing a neuroepithelial cell population from a stem cell population; and culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator.

[0060] In a preferred embodiment, the neuroepithelial cell population is an aggregate of neuroepithelial cells.

[0061] In a preferred embodiment, the choroid plexus organoids comprise: (a) epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by epithelium.

[0062] In some embodiments, the stem cells are embryonic stem cells. In some embodiments, the stem cells are induced pluripotent stem cells.

[0063] In some embodiments, culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a BMP signaling pathway activator is initiated less than 18 days, for example about 8-12 days, after initiation of culturing the stem cell population. In some embodiments, culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a BMP signaling pathway activator is initiated about 9-11 days after initiation of culturing the stem cell population. In some embodiments, culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a BMP signaling pathway activator is initiated about 9.5-10.5 days after initiation of culturing the stem cell population. In some embodiments, culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a BMP signaling pathway activator is initiated about 10 days after initiation of culturing the stem cell population.

[0064] In another aspect, the present invention provides a method for producing choroid plexus organoids, comprising: (a) generating an embryoid body population by culturing a stem cell population; (b) culturing the population of embryoid bodies under conditions suitable for neural induction; (c) embedding the product of step (b) in a three-dimensional matrix, preferably an extracellular matrix (ECM); (d) culturing the product of step (c) in the presence of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator, preferably beginning about 8-12 days after the initiation of step (a). The present invention provides a method comprising:

[0065] In some embodiments, the stem cells are embryonic stem cells. In some embodiments, the stem cells are induced pluripotent stem cells.

[0066] In some embodiments, the culturing in step (a) is for about 4 to 6 days, preferably about 4.5 to 5.5 days, preferably about 5 days.

[0067] In a preferred embodiment, the culture in step (b) is carried out until neuroepithelium is present. In some embodiments, the culture in step (b) is for about 1 to 3 days, preferably about 1.5 to 2.5 days, preferably about 2 days.

[0068] In some embodiments, the ECM is a polymerized ECM. In some embodiments, the ECM is a polymerized ECM gel. In some embodiments, the ECM is Matrigel.

[0069] Thus, in some embodiments, step (c) is performed about 5 to 9 days after the initiation of culture. , more preferably after 6-8 days, most preferably after 7 days, using Matrigel.

[0070] In some embodiments, step (c) further comprises culturing the embedded embryoid bodies. In some embodiments, the culturing in step (c) is for about 2-4 days, preferably about 2.5-3.5 days, preferably about 3 days.

[0071] In some embodiments, step (d) is initiated about 9-11 days, preferably about 9.5-10.5 days, preferably about 10 days, after the initiation of step (a).

[0072] In some embodiments, the culture in the presence of a WNT pathway activator and a BMP signaling pathway activator is for about 6-8 days, preferably about 6.5-7.5 days, preferably about 7 days.

[0073] In a preferred embodiment, the culturing in step (d) comprises agitation.

[0074] In some embodiments, agitation is not applied during contact with the WNT pathway activator and the BMP signaling pathway activator, hi some embodiments, agitation is initiated at about day 15.

[0075] In some embodiments, the method includes feeding the cultures with culture medium every 3-4 days starting on day 15, and optionally adding ECM to the culture medium starting on day 30. Preferably, the ECM is a soluble ECM - for example, dissolved Matrigel.

[0076] In a preferred embodiment, the method is an in vitro method.

[0077] In some embodiments, the WNT pathway activator is selected from the group consisting of CHIR99021, Wnt1, Wnt2, Wnt3, Wnt3a, Wnt8a, Wnt8b, Wnt10a, Wnt10b, BML-284, 6-bromoindirubin-3'-oxime (BIO), WAY-316606, IQ1, QS11, SB-216763, LY2090314, DCA, 2-amino-4-[3,4-(methylenedioxy)benzyl-amino]-6-(3-methoxyphenyl)pyrimidine and lithium.

[0078] In a preferred embodiment, the WNT pathway activator is CHIR99021.

[0079] In some embodiments, the BMP signaling pathway activator is selected from the group consisting of Bmp4, Bmp2, Bmp3, Bmp5, Bmp6, Bmp7, Bmp8a, Bmp8b, Bmp10, Bmp11, Bmp15, isoliquiritigenin, 4'-hydroxychalcone, apigenin, diosmetin and ventromorphins (e.g., SJ000291942, SJ000063181 and / or SJ00037178).

[0080] In a preferred embodiment, the BMP signaling pathway activator is Bmp4.

[0081] In a preferred embodiment, the WNT pathway activator is CHIR99021 and the BMP signaling pathway activator is Bmp4.

[0082] In some embodiments, the method or use does not include contacting the cell with a WNT pathway inhibitor.

[0083] In some embodiments, the method or use does not include exposing the cells to high oxygen tension, e.g., oxygen tension higher than the oxygen tension of air (20%). The method or use comprises culturing only under an oxygen tension of 20% or less.

[0084] As explained above, as part of its selective barrier function, the ChP epithelium is also highly selective for small molecules, including therapeutic agents. The present invention is particularly useful in the study and screening of CNS active drugs.

[0085] After progressing through clinical trials, new drugs too often fail due to lack of efficacy, inability to penetrate the CNS, or limited translatability across animal models (52).

[0086] The present ChP organoids may be useful, for example, in in vivo preclinical testing and modeling of drug permeability to the CNS, which may offer advantages compared to current standards for preclinical assays of CNS permeability (e.g., artificial membrane assays based on canine MDCK or Caco-2 cells or phospholipid mixtures lacking transporter and carrier proteins (53)).

[0087] In another embodiment, the present invention provides the use of choroid plexus organoid of the present invention for drug discovery screening or drug toxicity assay.Drug can be CNS drug, for example small molecule drug, for neurodegenerative disease such as Alzheimer's disease.

[0088] In some embodiments, this use is for testing the ability of candidate drug to pass and / or selectively pass through blood-cerebrospinal fluid (CSF) barrier.In another aspect, the present invention provides a method for testing the ability of candidate drug to pass through blood-cerebrospinal fluid (CSF) barrier, comprising contacting choroid plexus organoid of the present invention with candidate drug and determining whether candidate drug passes through epithelium. [Brief description of the drawings]

[0089] [Figure 1] Generation of choroid plexus organoids from human PSCs. (A) Protocol timeline showing different images from H9 organoid growth stages. BMP4 and Wnt activator CHIR are added on day 10 of the protocol to promote dorsalization. Scale bar: 1000 μm. (B) Comparison of H1 treated choroid plexus (ChP) organoids with untreated (UT) forebrain organoids on day 55. Scale bar: 1 mm. (C) H&E stained sections of H1 forebrain and choroid plexus organoids on day 40. Scale bar: 500 μm. (D) Histological sections of E18.5 mouse embryonic brain (H&E stained), human fetal ChP at 15 weeks post-gestation (Nissl stained, taken from Allen Brain Map http: / / portal.brain-map.org / ), and H1 human ChP organoids on day 40 (H&E stained). Scale bar: 500 μm, 50 μm for magnification. (E), (F) Representative confocal images of IMR90-4 iPSC-derived forebrain and ChP organoids stained for TTR (grey, anti-sheep Alexafluor 647), ZO1 (green, anti-mouse Alexafluor 488) and Sox2 (magenta, anti-rabbit Alexafluor 568) on days 28 (E) and 39 (F). Blue nuclei are DAPI stained. Scale bar: 100 μm. (G) Quantification of the percentage of TTR-positive area relative to the total organoid area in n=4 independent H9 batches (3-4 organoids for each batch harvested on days 30, 40 and 48). [Diagram 2]Organoids recapitulate the histological features of the human choroid plexus. (A) Representative confocal images of ChP epithelium from H1 organoids at day 40 stained positive for TTR (red, anti-sheep Alexafluor 568), CLIC6 (green, anti-rabbit Alexafluor 488) and ZO1 (grey, anti-mouse Alexafluor 647). Scale bar: 50 μm. (B) Immunoblots from untreated (UT) and BMP4- and CHIR-treated ChP organoids (n=3 independent H9 batches harvested at days 75, 73 and 68) probed for TTR, FOXG1, CLIC6 and the endogenous control GAPDH. (C) Immunoblot quantification showing accumulation of TTR and CLIC6 in ChP-treated organoids. (D) Representative confocal images of H1 organoids at day 30 and 46 stained for Krt18 (green, anti-mouse Alexafluor 488), 5HT-2C (magenta, anti-rabbit Alexafluor 568), PH3 (grey, anti-rat Alexafluor 647) and DAPI in blue. Scale bar: 50 μm. (E) Confocal images of ChP epithelial and stromal tissue from organoids stained positive for TTR (magenta) and DLK1 (green, anti-rabbit Alexafluor 488). Scale bar: 100 μm. (F) UMAP showing population composition identified by scRNAseq of all combined samples (telencephalic organoids harvested at day 55, ChP organoids harvested at days 27, 46 and 53). (G) UMAP showing the gradual accumulation of ChP populations in treated organoids compared to telencephalic organoids. (H) UMAP showing the enrichment of genes involved in ChP development and maturation (CLIC6, HRT2C, MSX1, PAX6), cortical neuron marker DCX and interstitial marker COL1A1 in the identified scRNAseq clusters. (I) Violin plot showing the expression levels of ChP immature / hem (OTX2, RSPO3, PAX6), mature (TTR, KRT18, CA2, NME5, KCNJ13, CA12) and interstitial markers (LUM, DCN, DLK1) identified by scRNAseq analysis. [Diagram 3]Choroid plexus organoids develop specialized epithelial features and closely recapitulate the genetic architecture of human in vivo tissue. (A) PCA of E18.5 mouse embryonic whole ChP and isolated ChP epithelial cells (EC) with organoid clusters from scRNA-seq. (B) Pearson correlation analysis of organoid clusters with in vivo human samples. (C) Color-coded heatmap showing unbiased clustering of in vivo human samples and organoids. (D) Pearson correlation analysis of mouse, human and organoid samples. (E) Violin plot showing expression of DYNLRB2, FOXJ1 and AQP1 in organoid cell populations identified by scRNAseq. (F) Confocal images of H1 ChP organoids at day 40 and 46, respectively, stained for CCDC67 (green, anti-rabbit Alexafluor 488), TTR (grey, anti-sheep Alexafuor 647), Foxj1 (magenta, anti-mouse Alexafluor 568), Arl13b (green, anti-rabbit Alexafluor 488) and DAPI in blue. Scale bars: 50 μm and 100 μm (magnified image: 20 μm). (G) Electron microscopy images showing widespread microvilli on the apical side of the ChP epithelium from organoids. Arrows indicate cilia (C), tight junctions (TJs), multivesicular bodies (MVBs) and extracellular vesicles (Ex). Scale bar: 1 μm. (H) Confocal images of day 40 H1 ChP organoids and in vivo ChP from mouse embryos (E18.5) stained positive for Aqp1 (magenta, anti-rabbit Alexafluor 568) and TTR (green, anti-sheep Alexafluor 488), blue nuclei are DAPI stained. Scale bar: 50 μm. (I) Violin plot showing expression levels of APOE, CLU, PLTP in organoid cell clusters identified by scRNAseq. (J) Representative confocal images of day 30 and day 46 H1 organoids stained for lipid droplets (LipidTox, grey), TTR (magenta, anti-sheep Alexafluor 568), PH3 (green, anti-rat Alexafluor 488) and blue DAPI. Scale bar: 50 μm.(K) Violin plot showing the expression levels of regional ChP markers in the lateral ventricle (LV, LY6E), third ventricle (3V, INS) and fourth ventricle (4V, PENK). [Figure 4] Choroid plexus organoids develop fluid-filled compartments and form tight barriers. (A) Violin plot showing expression levels of claudins 1, 3 and 5 in organoid cell clusters identified by scRNAseq. (B) UMAP showing accumulation of tight junction proteins in different organoid populations and ChP immature and mature clusters. Visualization of tight junction proteins TJP1 and TJP2, occludin (OCLN), INADL and MPDZ. (C) Representative images of day 40 human H1 ChP organoids stained positive for TTR (magenta, anti-sheep Alexafluor 568), claudin 1 (green, anti-rabbit Alexafluor 488) (D), claudin 3 (green, anti-rabbit Alexafluor 488) (E), claudin 4 (red, anti-mouse Alexafluor 568) and claudin 5 (green, anti-rabbit Alexafluor 488) (F). Nuclei in blue are labeled with DAPI. Scale bar: 50 μm. (D) Representative brightfield images of untreated forebrain organoids and ChP organoids that have developed fluid-filled compartments. Scale bar: 1 cm. Magnified brightfield image of a ChP organoid that has developed free-standing fluid compartments. Scale bar: 1 mm. (E) Confocal images of the epithelium surrounding the fluid-filled compartment of an organoid stained positive for ZO1 (grey, anti-mouse Alexafluor 647), TTR (green, anti-sheep 488), and Aqp1 (red, anti-rabbit Alexafluor 568). Nuclei are labeled in blue with DAPI. Scale bar: 50 μm. [Diagram 5]Human developmental proteins are secreted by choroid plexus organoids. (A) gProfileR analysis of proteins detected in iCSF from at least two organoid batches showing significant (p<0.05) enrichment for GO categories cellular component (GO:CC), molecular function (GO:MF) and biological process (GO:BP), REAC, WP, HP databases. (B) Color-coded heatmap showing relative abundance (emPAI values) of proteins detected in organoid iCSF from at least two organoid batches (3 H9 batches, 1 H1 and 1 iPSC batch) and their corresponding values ​​in culture medium and in an in vivo CSF ​​sample pool including human adult CSF (hCSF, telencephalic CSF, n=3 healthy donors, Caltag-Medsystem), bovine fetal CSF (bCSF, BioIVT) and embryonic mouse CSF (msCSF, E12.5-13.5). Values ​​shown are the average of proteins with emPAI >= 1. (C) Violin plot of secreted protein IGFBP7 and SERPINF1 expression levels in organoid cell clusters identified by scRNAseq analysis. (D) UMAP showing the enrichment of secreted proteins RBP1, IGF2, NPC2 and specific transporters SLC23A2 and SLC46A1 in different cell populations identified by organoid scRNAseq. (E) Venn diagram plot of CSF proteins present in human early embryo (Carnegie developmental stage 20), adult and ChP organoids. (F) Heatmap (emPAI values) with two colors: top, abundant proteins with emPAI >= 1 detected only in human-derived samples (organoid iCSF and adult hCSF); bottom, developmentally related abundant proteins with emPAI >= 1 detected only in organoid iCSF and embryonic or fetal in vivo CSF. (G) Immunoblot validation of IGF2 and TTR in organoid whole lysates from H9 untreated and treated ChP organoids, medium and iCSF from three independent batches. (H) Representative confocal images of ChP epithelium from organoids stained positive for IGF2 (green, anti-rabbit Alexafluor 488) and TTR (grey, anti-sheep Alexafluor 647). Nuclei are labeled with DAPI in blue.Scale bar: 100 μm. [Figure 6] Choroid plexus organoids model human brain barrier permeability. (A) Relative quantification of NMR spectra of dopa and L-dopa in medium and iCSF. (B) Relative NMR spectra of bupropionil, methotrexate and vincristine in medium and iCSF after 2 hours of incubation. (C) Relative NMR spectra of sephin 1 in medium and iCSF after 2 hours of incubation. (D) Representative images of ChP epithelium from organoids stained positive for TTR (grey, anti-sheep Alexafluor 647), LAT1 (magenta, anti-mouse Alexafluor 568), Pgp (green, anti-rabbit Alexafluor 488), transporters MRP4 (green, anti-rabbit Alexafluor 488) and MRP1 (green, anti-rabbit Alexafluor 488). Scale bar: 50 μm. Nuclei are labeled in blue by DAPI. (E) Pharmacokinetic model showing correlation (R2=0.9921; slope=1.004) between in vivo CSF / plasma ratio (Kp,uu,CSF) of unbound drug and in vitro iCSF / media ratio (Km,uu,iCSF) (Supplementary Table 5). Sephin1 (red dots) in vivo CSF / plasma measurements have been reported to have much higher values ​​in mice than those detected in human organoids (45). (F) Relative quantification of NMR spectra of BIA 10-2474 in media and iCSF after 2 h incubation. (G) Time course analysis of the ratio of BIA 10-2474 and bupropionil in iCSF to media at 2, 12, 24, and 72 h. (All drugs were tested in n=3 independent experiments; Supplementary Table 2). [Figure 7](A) Confocal images of forebrain organoids with convoluted cuboidal ChP epithelium stained positive for markers TTR, ZO1 and Aqp1. Scale bar: 100 μm. (B) Comparison of day 14 treated ChP organoids with untreated forebrain organoids. Arrows point to elongated neuroepithelial sprouts in early treated ChP organoids. Scale bar: 1 mm. (C) Brightfield images of different stages of the protocol using the fiber seeding method. Scale bar: 1000 μm. (D) Representative confocal images of H9 ChP organoids generated using the round and fiber method at days 30 and 34, respectively. Scale bar: 500 μm. (E) Representative confocal images of day 35 iPSC IMR90-4 organoids and day 40 H1 organoids treated with BMP4 and CHIR at day 10. ChP tissue in organoids was stained for TTR (green, anti-sheep Alexafluor 488) and nuclei were visualized with DAPI. Scale bar: 1000 μm (extraction: 500 μm). [Figure 8] (A) Representative confocal images of H1 forebrain and ChP organoids stained for Sox2 (magenta, anti-rabbit Alexafluor 568), cortical intermediate progenitor marker Tbr2 (grey, anti-sheep Alexafluor 647), neuronal marker HuC / D (green, anti-mouse Alexafluor 488). Scale bar: 100 μm. (B) Representative confocal images of H1 ChP organoids stained for DCN (green, anti-mouse Alexafluor 488), LUM (magenta, anti-rabbit Alexafluor 568), ZO1 (grey, anti-mouse Alexafluor 647), TTR (grey, anti-sheep Alexafluor 647) and DAPI in blue. Scale bar: 100 μm. [Figure 9](A) Representative brightfield images of four independent batches of H1-untreated and BMP4+CHIR-treated organoids (top to bottom: 57, 54, 46, 40 days). (B) Time course of images of H1-treated ChP organoids showing the emergence and expansion of the iCSF compartment from day 14 to day 50. Scale bar: 1000 μm. (C) Immunoblots of ChP organoid lysates from day 10 to day 31 for ChP epithelial transporters MRP1, LAT1, CLIC6, secreted protein IGF2 and loading control GAPDH. [Figure 10] (A) Venn diagram of proteins detected by mass spectrometry with emPAI ≥ 1 in at least one sample in media, organoid iCSF and in vivo CSF ​​samples. (B) Color-coded heat map of the same proteins from Figure 3E showing all samples analyzed by mass spectrometry. Proteins with emPAI ≥ 1 detected in at least two iCSF samples are shown. (C) Color-coded heat map showing high abundance proteins (emPAI ≥ 1) shared between media and iCSF from at least two organoid batches (average of 5 samples shown) and average of in vivo CSF ​​samples from human adult CSF (hCSF), bovine fetal CSF (bCSF) and embryonic mouse CSF (msCSF, E12.5-13.5). (D) Color-coded heat map of high abundance proteins (emPAI ≥ 1) excluded or absent from organoid iCSF but present in at least two in vivo samples. (E) gProfileR analysis of proteins detected only in in vivo CSF ​​samples. (F) Histogram showing top categories from gProfileR analysis with significant (p<0.05) enrichment. [Figure 11](A) ChP epithelium from human organoids stained for TTR (grey, anti-sheep Alexafluor 647), claudin 2 (green, anti-rabbit Alexafluor 488) and APOE (magenta, anti-mouse Alexafluor 568). Scale bar: 50 μm. Blue DAPI labels nuclei. (B) ChP epithelium from human organoids stained for tight junction markers occludin (green, anti-rabbit Alexafluor 488), TTR (grey, anti-sheep Alexafluor 647), ZO1 (magenta, anti-mouse Alexafluor 568) and blue DAPI. Scale bar: 50 μm. (C) Brightfield image of ChP organoids with free-standing iCSF fluid isolated from cultures incubated with 647-Alexafluor-labeled 10 kDa dextran for 2 h. (D) Fluorescence intensity measured in medium and iCSF after 2 h incubation with 70 kDa Oregon Green-dextran, 10 kDa Alexa 647-dextran and 3-5 kDa FITC-dextran. (E) NMR spectra of Dopa, L-Dopa and control (Ctrl) iCSF measured after 2 h incubation. [Figure 12] (A) 1H-NMR analysis (H2O / D2O) of control samples (medium and iCSF). Expanded portions of the spectra are reported for clarity. (B) 1H-NMR analysis (H2O / D2O) of samples incubated with L-dopa (500 μM) and carbidopa (500 μM). (C) 1H-NMR analysis (H2O / D2O) of samples incubated with dopamine (500 μM) (500 μM). Arrows indicate peaks of interest. [Figure 13] (A) H-NMR analysis (HO / DO) of samples (medium and iCSF) upon incubation with (A) Sephin1 (500 μM), (B) Vincristine (500 μM), (C) Methotrexate (500 μM). For clarity, enlarged portions of the spectra are reported. Arrows indicate peaks of interest. [Figure 14](A) 1H-NMR analysis (H2O / D2O) of samples (medium and iCSF) upon incubation with bupropionil (500 μM). For clarity, an expanded portion of the spectrum is reported. The arrow indicates the peak of interest. [Figure 15] (A) 1H-NMR analysis (H2O / D2O) of samples (medium and iCSF) upon incubation with BIA10-2474 (500 μM). For clarity, an expanded portion of the spectrum is reported. The arrow indicates the peak of interest. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0090] Detailed Description of the Invention The terms "comprising", "including" and "comprising" as used herein are synonymous with "including" or "comprising"; or "containing" or "comprising" and are inclusive or open-ended and do not exclude additional, unrecited members, elements or steps. The terms "comprising", "including" and "comprising" also include the term "consisting of".

[0091] Organoids Organoid is a three-dimensional (3D) in vitro cell culture. Organoid can provide a miniaturized and simplified version of an organ, and incorporate some important characteristics of the organ. Such an in vitro culture system can contain a self-renewing stem cell population that differentiates into multiple organ-specific cell types with similar spatial organization as the organ.

[0092] choroid plexus The choroid plexus is a highly conserved secretory tissue in the brain that serves several important functions, including formation of a protective epithelial barrier and secretion of cerebrospinal fluid (CSF).

[0093] Anatomically, the choroid plexus is localized in the lateral, third, and fourth ventricles, occurring in their respective lumen. The mature choroid plexus consists of a simple cuboidal epithelium surrounding a core of mesenchymal-derived stromal tissue and fenestrated capillaries. The epithelial cells are tightly connected by tight junctions and are highly polarized, with an apical brush border facing the ventricular lumen and a basal surface facing the interstitium.

[0094] CSF production involves several mechanisms. First, Na+ is released from the apical side of choroid plexus epithelial cells. + -K + The ATPase pump and cytosolic carbonic anhydrase pump primarily transport Na into the ventricular lumen. + This osmotic force drives the transcellular influx of water through aquaporin channels. Secondly, ATP-binding cassette (ABC) proteins and solute carrier transporters (SLCs) allow the exchange of amino acids, nucleosides and small peptides that require and do not require ATP hydrolysis, respectively. Choroid plexus epithelial cells also express efflux transporters such as MRP1 and MRP4 (Redzic, Z. (2011) Fluids Barriers CNS 8: 3;Strazielle, N. and Ghersi-Egea, JF (2013) Mol. Pharm. 10: 1473-1491). These pumps regulate the clearance of metabolites and prevent the entry of drugs and toxic compounds, thus reducing their availability in the CSF. Third, the secretory system of choroid plexus epithelial cells is highly specialized and extensive, allowing for the secretion of more complex proteins and hormones. For example, transthyretin (TTR), a carrier of thyroid hormones and retinol, is the most abundant protein synthesized and secreted by the choroid plexus (Li, X. and Buxbaum, JN (2011) Mol. Neurodegener. 6: 1-17;Richardson, SJ et al. (2015) Front. Neurosci. 9: 1-8;Johnson, BA et al. (2018) Fluids Barriers CNS 15: 22). TTR-mediated vasoconstriction into the CSF is thought to be due to the increased secretion of thyroid hormones and thyroid hormones. Glandular hormone delivery appears to have an important role in regulating brain development.

[0095] Choroid plexus tissue can be identified by the expression of choroid plexus markers and / or architectural characteristics of the tissue.

[0096] The choroid plexus may be characterized by the expression of one or more markers selected from the group consisting of transthyretin (TTR), MRP1, MRP4, aquaporin 1 (Aqp1) and zonula occludens (ZO1).

[0097] The choroid plexus may be characterized by the expression of markers that are localized or accumulated in particular types of cells, for example, the choroid plexus may be characterized by the expression of one or more markers selected from the group consisting of TTR, MRP1, MRP4, Aqp1, and ZO1 in epithelial cells.

[0098] In addition, these markers may localize or accumulate in specific regions of specific cells. For example, TTR, Aqp1 and / or ZO1 may accumulate on the apical side of the epithelium. MRP1 and / or MRP4 may accumulate on both the apical and basal sides of the epithelium.

[0099] The choroid plexus may be characterized by no or low expression of FOXG1.

[0100] The choroid plexus may be characterized by the presence of apical microvilli in the epithelium. The choroid plexus epithelium may contain centrally basally located nuclei.

[0101] The choroid plexus epithelium can have apical-basal polarity. For example, the epithelium can be polarized, with Aqp1 and ZO1 expressed on the luminal side of the epithelium.

[0102] The presence, absence and localization of such markers can be readily determined by one of skill in the art. For example, markers can be identified by immunostaining with antibodies specific for the marker in conjunction with visualization techniques such as confocal microscopy. Additionally or alternatively, specific oligonucleotide probes that preferably bind to marker nucleic acids can be utilized.

[0103] Tight epithelial barrier The tight epithelial barrier may be formed by tight junctions between epithelial cells.

[0104] Tight junctions (also called occluding junctions or zonula occludens) can be formed by multiprotein complexes and can block the paracellular pathway, preventing leakage of transported solutes and water.

[0105] The tightly sealed epithelium of the choroid plexus is also known as the blood-CSF barrier (B-CSF-B). Similar to the blood-brain barrier (BBB), B-CSF-B prevents toxic substances or signals in the circulation from reaching the brain. However, in contrast to the BBB, B-CSF-B is formed by a single cell type, the choroid plexus epithelial cells, which face the CSF rather than directly the brain parenchyma. However, CSF can freely enter and leave the brain, so the B-CSF-B is a barrier to the brain. Transport of molecules through the FB is an alternative pathway to the brain.

[0106] Tight junctions, such as those involved in the tight epithelial barrier, can be characterized by expression of the zonula occludens (ZO1).

[0107] Cerebrospinal fluid (CSF) Cerebrospinal fluid (CSF) is a clear, colorless liquid that circulates through the ventricles and subarachnoid space and is then partially reabsorbed into the blood circulation through the arachnoid granulations.

[0108] CSF is important for its protective role in maintaining physiological levels of nutrients in the brain, transporting signaling molecules and growth factors, and regulating intracranial pressure.

[0109] CSF is produced by active secretion from choroid plexus epithelial cells, which maximize the number of transporters and pumps in their apical brush border, and from blood filtration, which is conferred by the presence of tight junctions within choroid plexus epithelial cells. The choroid plexus plays a key role in maintaining the rate of CSF production and resorption. Disturbance of this balance leads to pathologies such as hydrocephalus.

[0110] CSF may be characterized by the presence of one or more markers selected from the group consisting of TTR, clusterin (CLU), apolipoprotein E (APOE), apolipoprotein A4 (APOA4), and lumican (LUM).

[0111] The CSF can be characterized by the presence of alpha-fetoprotein (AFP).

[0112] WNT pathway activator The WNT pathway activator that can be used to prepare the choroid plexus organoid of the present invention is not particularly limited, provided that it has the ability to activate the WNT signaling pathway.

[0113] WNT pathway activators include, but are not limited to, agents such as CHIR99021, Wnt1, Wnt2, Wnt3, Wnt3a, Wnt8a, Wnt8b, Wnt10a, Wnt10b, BML-284, 6-bromoindirubin-3'-oxime (BIO), WAY-316606, IQ1, QS11, SB-216763, LY2090314, DCA, 2-amino-4-[3,4-(methylenedioxy)benzyl-amino]-6-(3-methoxyphenyl)pyrimidine, and lithium.

[0114] In a preferred embodiment, the WNT pathway activator is CHIR99021 (also referred to herein as "CHIR").

[0115] CHIR99021 inhibits GSK3β (IC 50 = 6.7 nM) and GSK3α (IC 50 CHIR99021 is an aminopyrimidine derivative that is a highly potent GSK3 inhibitor that inhibits GSK3 (at least 10 nM) and functions as a WNT activator. [ka] has.

[0116] In some embodiments, CHIR99021 is used at a concentration of about 1-25, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, or 1-3 μM. In some embodiments, CHIR99021 is used at a concentration of about 1-5 μM.

[0117] In some embodiments, CHIR99021 is used at a concentration of about 2-25, 2-20, 2-15, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, or 2-4 μM. In a preferred embodiment, CHIR99021 is used at a concentration of about 2-4 μM.

[0118] In some embodiments, CHIR99021 is used at a concentration of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 μM. In a preferred embodiment, CHIR99021 is used at a concentration of about 3 μM.

[0119] Bone morphogenetic protein (BMP) signaling pathway activators The bone morphogenetic protein (BMP) signaling pathway activator that can be used to prepare the choroid plexus organoid of the present invention is not particularly limited, but it has the ability to activate the BMP signaling pathway.

[0120] BMP signaling pathway activators include, but are not limited to, agents such as Bmp4, Bmp2, Bmp3, Bmp5, Bmp6, Bmp7, Bmp8a, Bmp8b, Bmp10, Bmp11, Bmp15, isoliquiritigenin, 4'-hydroxychalcone, apigenin, diosmetin, and ventromorphins (e.g., SJ000291942, SJ000063181, and / or SJ00037178).

[0121] In a preferred embodiment, the BMP signaling pathway activator is Bmp4.

[0122] Bone morphogenetic protein 4 (Bmp4) is a member of the TGF-β protein superfamily. It is involved in bone and cartilage development, including tooth and limb development, and fracture repair.

[0123] In human embryonic development, Bmp4 is a key signaling molecule involved in early embryonic differentiation and establishment of the dorsal-ventral axis.

[0124] An exemplary amino acid sequence of human Bmp4 is available under NCBI accession number NP_001193.2. The sequence is that deposited at

[0125] An exemplary amino acid sequence of human Bmp4 is: [ka] It is.

[0126] In some embodiments, Bmp4 is used at a concentration of about 1-40, 5-35, 10-30, 15-25, 16-24, 17-23, 18-22, or 19-21 ng / ml. In some embodiments, Bmp4 is used at a concentration of about 19-21 ng / ml.

[0127] In some embodiments, Bmp4 is used at a concentration of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 ng / ml. In a preferred embodiment, Bmp4 is used at a concentration of about 20 ng / ml.

[0128] salt The agents of the invention (eg, WNT pathway activators and / or BMP signaling pathway activators) may be present as salts, particularly pharma- ceutically acceptable salts or esters.

[0129] Pharmaceutically acceptable salts of the agents of the present invention include suitable acid addition or base salts thereof. For a review of suitable pharmaceutical salts, reference may be made to Berge. et al. (1977) J. Pharm. Sci. 66: 1-19. Salts include, for example, strong inorganic acids such as mineral acids, for example sulfuric acid, phosphoric acid or hydrohalic acids; strong organic carboxylic acids, for example acetic acid, alkane carboxylic acids of 1 to 4 carbon atoms, unsubstituted or substituted (for example, by halogen); saturated or unsaturated dicarboxylic acids, for example oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, phthalic acid or tetraphthalic acid; hydroxycarboxylic acids, for example ascorbic acid, glycolic acid, lactic acid, malic acid, tartaric acid or citric acid; amino acids, for example aspartic acid or glutamic acid; benzoic acid; or unsubstituted or substituted (for example, by halogen), such as methanesulfonic acid or p-toluenesulfonic acid (C 1 ~C 4 )-alkylsulfonic acids or arylsulfonic acids.

[0130] Enantiomers / Tautomers The present invention also includes, where appropriate, all enantiomers and tautomers of the agents. The corresponding enantiomers and / or tautomers may be isolated / prepared by methods known in the art.

[0131] Stereoisomers and geometric isomers Some of the agents of the present invention can exist as stereoisomers and / or geometric isomers. For example, an agent may have one or more asymmetric centers and / or geometric centers and therefore can exist in two or more stereoisomeric and / or geometric forms. The present invention relates to all individual forms of such agents. The use of other stereoisomers and geometric isomers, and mixtures thereof, is contemplated, and the terms used in the claims encompass these forms, provided said forms retain the appropriate functional activity (though not necessarily to the same degree).

[0132] The present invention also includes all suitable isotopic variations of the agent or its pharma- ceutically acceptable salts. An isotopic variation of the agent or its pharma- ceutically acceptable salts of the present invention is defined as one in which at least one atom has been replaced by an atom having the same atomic number, but whose atomic mass is different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into the agent and its pharma- ceutically acceptable salts are: 2 H, 3 H, 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F and 36 Specific isotopic variations of the agent and its pharma- ceutically acceptable salts, e.g., 3 H or 14 Those incorporating radioactive isotopes such as C are useful for drug and / or substrate tissue distribution studies. Tritiated isotopes, i.e. 3 H and carbon 14, i.e. 14 C isotopes are particularly preferred for their ease of preparation and detectability. Additionally, deuterium, i.e. 2 Substitution with isotopes such as H may confer certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in some circumstances. Isotopic variations of the agents of the invention and pharma- ceutically acceptable salts thereof of the invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.

[0133] solvate The present invention also includes solvated forms of the agents of the invention and the terms used in the claims encompass such forms.

[0134] polymorphism The present invention also relates to the inventive agents in their various crystalline, polymorphic and (an)hydrous forms. Within the pharmaceutical industry, it is well established that chemical compounds can be isolated in any of these forms by slightly altering the purification and / or separation methods from the solvents used in the synthetic preparation of such compounds.

[0135] stem cells The choroid plexus organoid of the present invention can be produced (for example, in vitro) from stem cells.This choroid plexus organoid is not isolated from animal brain, so it is not necessary to obtain tissue samples from animals, and tissue can be easily produced.

[0136] Stem cells are cells that have the potential to differentiate into more specialized cells and can also divide to produce more stem cells.

[0137] With the decrease in differentiation ability, stem cells differentiate in the following order: pluripotency, multipotency, unipotency.During the development of the organoid of the present disclosure, stem cells can differentiate, for example, from pluripotent neural stem cells to multipotent neural stem cells, and then to unipotency stem cells, and then to non-stem tissue cells.This tissue cell can be, for example, neuroepithelial cells.

[0138] The methods of the invention can include contacting a progenitor cell population (e.g., a neuroepithelial cell population) with a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator, where the progenitor cell population itself has been generated (e.g., in vitro) by differentiation of a stem cell population.

[0139] Thus, the methods of the invention may include the step of generating a cell population (eg in vitro) from a stem cell population.

[0140] Preferably, the stem cells of the present invention are pluripotent stem cells.

[0141] Pluripotent stem cells are stem cells that can grow indefinitely.Pluripotent stem cells do not have the ability to grow into a complete organism, but they have the ability to give rise to cell types derived from all three germ layers, namely mesoderm, endoderm and ectoderm, and can differentiate into any cell type in the human body.Such stem cells are expected to provide a single source of cells that can replace cells affected by damage or disease.

[0142] Pluripotent stem cells can be produced by a number of techniques, such as by creating induced pluripotent stem cells or embryonic stem cells.

[0143] In some embodiments, the stem cells of the present invention are induced pluripotent stem cells (iPSCs).

[0144] iPSCs are a type of pluripotent stem cell that can be directly generated from adult cells. Those skilled in the art can easily prepare iPSCs, for example, by introducing specific transcription factors into adult cells or by contacting adult cells with a combination of specific proteins.

[0145] Comparing iPSCs to embryonic stem cells, iPSCs have the advantage that they can be prepared from the subject to which they (or cells generated therefrom) are subsequently reintroduced, obviating the need to use embryonic material. Such autologous cell transplantation may eliminate the risk of immune rejection of the transplanted material.

[0146] The stem cells of the present invention may be embryonic stem cells, particularly those generated without the destruction of an embryo.

[0147] Methods for generating pluripotent stem cells, such as mammalian embryonic stem cells, without the destruction of the embryo are known in the art. In particular, it has been shown that mouse and human embryonic stem cells can be generated from a single blastomere while keeping the embryo intact. For example, Chung, Y. et al. (2006) Nature 439: 216-219 describes a method for making mouse embryonic stem cells from a single blastomere. This procedure was later improved to provide a method that did not require co-culturing blastomere cell lines with other ESCs (Chung, Y. et al. (2008) Cell Stem Cell 2: 113-117).

[0148] In some embodiments, the stem cells of the present invention are mammalian stem cells, preferably human stem cells.

[0149] How to generate choroid plexus organoids The choroid plexus organoids of the present invention can be generated using WNT pathway activators and bone morphogenetic protein (BMP) signaling pathway activators.

[0150] In one aspect, the present invention provides the use of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator to generate choroid plexus organoids, wherein the choroid plexus organoids comprise: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by the epithelium.

[0151] In another aspect, the present invention provides a method for producing choroid plexus organoids, comprising contacting a neuroepithelial cell population with a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator, wherein the choroid plexus organoids comprise: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by the epithelium.

[0152] In another aspect, the present invention provides a method for preparing choroid plexus organoid, comprising: preparing neuroepithelial cell population from stem cell population; and culturing neuroepithelial cell population in the presence of WNT pathway activator and bone morphogenetic protein (BMP) signaling pathway activator.In a preferred embodiment, choroid plexus organoid comprises (a) epithelium that comprises tight epithelial barrier; and / or (b) one or more cysts surrounded by epithelium.

[0153] In some embodiments, the stem cells are embryonic stem cells. In some embodiments, the stem cells are induced pluripotent stem cells.

[0154] In a preferred embodiment, the neuroepithelial cell population is an aggregate of neuroepithelial cells.

[0155] In a preferred embodiment, the neuroepithelial cell population is embedded in a three-dimensional matrix, preferably an extracellular matrix (ECM), prior to contact with a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator.

[0156] In some embodiments, culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a BMP signaling pathway activator is initiated about 8-12 days after initiation of culturing the stem cell population. In some embodiments, culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a BMP signaling pathway activator is initiated about 9-11 days after initiation of culturing the stem cell population. In some embodiments, culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a BMP signaling pathway activator is initiated about 9.5-10.5 days after initiation of culturing the stem cell population. In some embodiments, culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a BMP signaling pathway activator is initiated about 10 days after initiation of culturing the stem cell population.

[0157] In some embodiments, the method or use preferably comprises agitation after contacting with the WNT pathway activator and the BMP signaling pathway activator. Agitation can be achieved, for example, using a shaker, such as an orbital shaker.

[0158] In another aspect, the present invention provides a method for producing choroid plexus organoids, comprising: (a) generating an embryoid body population by culturing a stem cell population; (b) culturing the population of embryoid bodies under conditions suitable for neural induction; (c) embedding the product of step (b) in a three-dimensional matrix, preferably an extracellular matrix (ECM); (d) culturing the product of step (c) in the presence of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator, preferably beginning about 8-12 days after the initiation of step (a). The present invention provides a method comprising:

[0159] Embryoid bodies (EBs) are three-dimensional aggregates of pluripotent stem cells that undergo spontaneous or directed differentiation.

[0160] The methods and uses of the present invention may comprise embedding cells or cell aggregates in a three-dimensional matrix, preferably an extracellular matrix (ECM).

[0161] In some embodiments, the ECM is a polymerized ECM. In some embodiments, the ECM is a polymerized ECM gel. A suitable three-dimensional matrix may include collagen. Preferably, the three-dimensional matrix is ​​an ECM secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells or any component thereof, such as laminin, collagen, type 4 collagen, entactin, and optionally further heparan sulfate proteoglycans. or any combination thereof. In some embodiments, the ECM is Matrigel. Matrigel is described, for example, in U.S. Patent No. 4,829,000.

[0162] Typically, the three-dimensional matrix is ​​a three-dimensional structure of a biocompatible matrix. It preferably comprises collagen, gelatin, chitosan, hyaluronan, methylcellulose, laminin and / or alginate. The matrix may be a gel, in particular a hydrogel. Organochemical hydrogels may comprise polyvinyl alcohol, sodium polyacrylate, acrylate polymers and copolymers containing a large amount of hydrophilic groups. Hydrogels comprise a network of hydrophilic polymer chains and are sometimes seen as colloidal gels in which water is the dispersion medium. Hydrogels are natural or synthetic polymers that are highly absorbent (hydrogels can contain more than 99% water). Due to their high water content, hydrogels also have a certain degree of flexibility, much like natural tissues.

[0163] The generation of an embryoid body population may be carried out by culturing a stem cell population in a suitable medium, referred to herein as embryoid body (EB) medium.

[0164] An exemplary EB medium comprises a serum replacement product, fetal bovine serum, glutamine, non-essential amino acids, 2-mercaptoethanol and FGF (e.g., basic FGF) (preferably about 4ng / ml bFGF). Preferably, the EB medium comprises a ROCK inhibitor. Preferably, the EB medium comprises a ROCK inhibitor only for the first 3 days of stem cell culture.

[0165] A particularly suitable medium is the EB medium used in this example or the EB medium disclosed below.

[0166] Neural induction can be performed by culturing in a suitable medium, referred to herein as neural induction medium. The neural induction medium can be, for example, a depleted medium lacking serum or serum substitutes. The absence of such nutrients required for non-neural tissues can result in the loss of other non-neural identities and purification towards a neural identity.

[0167] An exemplary neural induction medium is N2 supplement (Price and Brewer (2001) Protocols for Neural Cell Culture 255-264; e.g., Invitrogen, catalog number 17502048). , glutamine, non-essential amino acids and heparin.

[0168] A particularly suitable medium is the neural induction medium used in this example or the neural induction medium disclosed below.

[0169] In a preferred embodiment, individual embryoid bodies are embedded in separate three-dimensional matrix droplets.

[0170] Embedding in a three-dimensional matrix can be achieved by adding the embryoid bodies to a soluble matrix in a suitable container, followed by incubation under conditions suitable for polymerization of the matrix. For example, the embryoid bodies can be transferred one by one to a welled Parafilm. After removing excess medium, a drop of matrix (e.g., Matrigel) can be added to each embryoid body. The mixture can then be incubated under conditions suitable for polymerization of the matrix (e.g., at 37°C for about 20 minutes).

[0171] In a preferred embodiment, the embryoid bodies embedded in the three-dimensional matrix are cultured under conditions suitable for expansion. Expansion can be performed by culturing in a suitable medium (referred to herein as expansion medium).

[0172] Exemplary expansion media include N2 supplement (Price and Brewer (2001) Protocols for Neural Cell Culture 255-264; e.g., Invitrogen, Cat. No. 17502048), B27 supplement without tamamine A (Price and Brewer (2001) Protocols for Neural Cell Culture 255-264; e.g., Invitrogen, catalog number 12587010), insulin , 2-mercaptoethanol, glutamine and non-essential amino acids.

[0173] Particularly suitable media are the expansion media used in this example or those disclosed below.

[0174] The culturing in the presence of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator and subsequent culturing in the absence of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator may be carried out in a suitable medium, which may be referred to herein as a maturation medium.

[0175] An exemplary maturation medium includes N2 supplement (Price and Brewer (2001) Protocols for Neural Cell Culture 255-264; e.g., Invitrogen, Cat. No. 17502048), B27 supplement containing tamamine A (Price and Brewer (2001) Protocols for Neural Cell Culture 255-264; e.g., Invitrogen, catalog no. 17504044), insulin , 2-mercaptoethanol, glutamine and non-essential amino acids.

[0176] Particularly suitable media are the maturation media used in this example or those disclosed below.

[0177] Any medium may further comprise nutrients and / or buffers. Preferred nutrients include carbohydrates, especially monohexoses or monopentoses such as glucose or fructose.

[0178] Culture conditions suitable for use in the methods of the present invention include, for example: (a) culturing at about 36 to 39°C or 36.5 to 37.5°C, preferably about 37°C; (b) about 4-6% or 4.5-5.5% CO 2 , preferably about 5% CO 2and / or (c) culturing at a humidity of at least about 95%, 96%, 97%, 98%, or 99%, preferably at about 100% humidity; Examples include:

[0179] Further exemplary EB media includes (per 50 mL): 40 ml DMEM / F12 (Invitrogen Catalog No. 11330-032); 10 ml Knockout Serum Replacement (KOSR; Invitrogen Catalog No. 10828-028); 1.5 ml Embryonic Stem Cell Quality FBS; 0.5 ml GlutaMAX (Invitrogen Catalog No. 35050-038); 0.5 ml MEM Non-Essential Amino Acids (MEM-NEAA; Sigma Catalog No. M7145); 100 μl of 5 40 mM 2-ME (e.g., Life Technologies catalogue no. 31350-010); ng / ml bFGF (e.g., Peprotech Catalog No. 100-18B) (immediately prior to use) Add 1:2500; and 1:100 Rock inhibitor (Y27632; VWR catalog) The tag number is 688000-5 (add immediately before use).

[0180] Further exemplary neural induction media includes (per 100 mL): 100 ml DMEM / F12 (Invitrogen Catalog No. 11330-032); 1 ml N2 supplement (Invitrogen Catalog No. 17502048); 1 ml Glutamax supplement (Invitrogen Catalog No. 35050-038); 1 ml MEM-NEAA (Sigma Catalog No. M714 5); and 100 ul Heparin Solution (Sigma Cat. No. H3149).

[0181] Further exemplary expansion media include (per 250 mL): 125 ml DMEM / F12 (Invitrogen Catalog No. 11330-032); 125 ml Neurobasal medium (Invitrogen Catalog No. 21103049); 1.25 ml N2 supplement (Invitrogen Catalog No. 17502048); 5 ml B27 supplement (Invitrogen Catalog No. 12587010 or 17504044); 62.5 ul insulin (Sigma Catalog No. I 9278); 250 ul of 50 mM 2-ME solution (e.g., Life Technologies Catalog) 2.5ml Glutamax supplement (Invitrogen Catalog No. 35050-038); 1.25ml MEM-NEAA (Sigma Catalog No. M7 145); and 2.5 ml penicillin / streptomycin (Sigma Catalog No. P07 81).

[0182] Further exemplary maturation media include (per 250 mL): 125 ml DMEM / F12 (Invitrogen Catalog No. 11330-032); 125 ml Neurobasal medium (Invitrogen Catalog No. 21103049); 1.25 ml N2 supplement (Invitrogen Catalog No. 17502048); 5 ml B27 supplement (Invitrogen Catalog No. 12587010 or 17504044); 62.5 ul insulin (Sigma Catalog No. I 9278); 250 ul of 50 mM 2-ME solution (e.g., Life Technologies Catalog) 2.5ml Glutamax supplement (Invitrogen Catalog No. 35050-038); 1.25ml MEM-NEAA (Sigma Catalog No. M7 145); and 2.5 ml penicillin / streptomycin (Sigma Catalog No. P07 81).

[0183] Screening and Assay Methods In one aspect, the present invention provides the use of the choroid plexus organoids of the present invention for drug discovery screening or drug toxicity assays.

[0184] In some embodiments, the use is to test the ability of a candidate agent to cross the blood-cerebrospinal fluid (CSF) barrier.

[0185] In another embodiment, the present invention provides a method for testing the ability of a candidate agent to cross the blood-cerebrospinal fluid (CSF) barrier, comprising contacting the choroid plexus organoid of the present invention with the candidate agent and determining whether the candidate agent crosses the epithelium.

[0186] For example, candidate agent can be added to the culture medium of the culture that comprises choroid plexus organoid, and incubated.Then, for example, after a suitable time, the liquid in one or more cysts of choroid plexus organoid can be extracted and analyzed for the presence of candidate agent.The assay for the presence of candidate agent can be any suitable technique known to those skilled in the art.For example, the agent can be identified using mass spectrometry.

[0187] Those skilled in the art will understand that they may combine all of the features of the invention disclosed herein without departing from the scope of the invention as disclosed.

[0188] Preferred features and embodiments of the present invention will now be described by way of non-limiting examples.

[0189] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, biochemistry, molecular biology, microbiology and immunology, which are within the capabilities of one of ordinary skill in the art. Such techniques are explained in the literature, see, for example, Sambrook, J., Fritsch, EF and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press;Ausubel, FM et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, Ch. 9, 13 and 16, John Wiley & So ns;Roe, B., Crabtree, J. and Kahn, A. (1996) DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons;Polak, JM and McGee, J. O'D. (1990) In Situ Hybridization: Principles and Practice, Oxford University Press;Gait, MJ (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; and Lilley, See DM and Dahlberg, JE (1992) Methods in Enzymology: DNA Structures Part A: Synthesis and Physical Analysis of DNA, Academic Press. Each of these general texts is incorporated herein by reference. EXAMPLES

[0190] Materials and Methods stem cell culture Human H9 and H1 ES cells were obtained from WiCell and the studies were approved by the UKSCB Steering Committee. iPS cells (IMR90-4) were obtained from WiCell and all cell lines were confirmed to be pluripotent and mycoplasma-free. Cells were maintained in culture and fed with StemFlex culture medium (Gibco A3349401).

[0191] Brain and choroid plexus organoid culture conditions Embryoid bodies (EBs) were prepared from single cell suspensions from hES and iPSCs as previously described (1). Brain and ChP organoids were generated using Stem Cell Technologies Brain Organoid Kit (cat. no. 08570, 08571) reagents. EBs were generated either using fibrous microscaffolds and 18,000 hES or iPS cells in each case to increase surface area and improve neural induction efficiency, or using fewer cells (2000–4000) in the absence of microscaffolds to generate smaller EBs, as previously described (2). These were plated in 96-well U-bottom low-attachment plates in EB medium and 50 μM Y-27632 ROCK inhibitor for 3 days, followed by 2 days in EB medium alone. On day 5, medium was replaced with NI medium in the same 96-wells. After 2 days, EBs were embedded in 20 μl matrigel using a sheet of indented parafilm and incubated at 37 °C for 20 min, as previously described (2). EBs were then transferred to 6-well plates with 3 ml of expansion medium for each well. For ChP patterning, treatment with 3 μM CHIR and 20 ng / ml BMP4 in maturation medium was used on day 10, keeping a maximum number of six EBs in each 5 cm dish. This treatment continued for 7 days in maturation medium. On day 15, organoids were transferred to an incubator with a shaker and maturation medium was replenished every 3–4 days. Starting on day 30, dissolved matrigel (1:50) was added to the maturation medium.

[0192] Immunostaining and immunoblotting Organoids were fixed in 4% PFA overnight at 4°C, then washed three times with PBS for 10 min each, and then transferred to 30% sucrose buffer at 4°C for at least 24 h. Organoids were then embedded in gelatin and sectioned as previously described (1). After blocking and permeabilization with 0.25% Triton and 1% donkey serum buffer, sections were incubated overnight with the following primary antibodies: sheep anti-TTR (1:500, Abcam, ab9015), mouse ... Mouse anti-ZO1 (1:300, BD Transduction, 610966), rabbit anti-Aqp1 (1 :200, Abcam ab15080), mouse anti-MRP1 (1:200, Abcam ab24102), rabbit anti-MRP4 (1:200, Cell Signaling Technology, 12705) , rabbit anti-Sox2 (1:300, Abcam, ab97959), rabbit anti-CLIC6 (immuno 1:500 for immunostaining, 1:1000 for immunoblotting, Abcam, ab204 567), rabbit anti-Foxg1 (1:200 for immunostaining, 1:1000 for immunoblotting, Abcam, ab18259), mouse anti-GAPDH (1:1000, Abcam, ab8245), rabbit anti-IGF2 (1:200 for immunostaining, 1:1000 for immunoblotting, Abcam, ab9574), rat anti-histone H3 phosphorylation (PH3, 1:300, Abcam ab10543), mouse anti-keratin 18 (Krt18, 1:20 0, Novus biologicals NBP2-47985), rabbit anti-serotonin (5HT2C, rabbit anti-CCDC67 (1:200, Abcam ab102688), mouse anti-Foxj1 (1:100, Thermo Fisher 14-9965-8 2); rabbit anti-Arl13b (1:200, Proteintech 17711-1-AP), Heron anti-DLK1 (1:200, Abcam, ab21682), sheep anti-Tbr2 (1:20 0, R&D Systems, AF6166), mouse anti-HuC / D (1:500, LifeTech, A21271), mouse anti-LAT1 (1:50, Santa Cruz, sc-374232), rabbit anti-Pgp / MDR1 (1:200, Cell Signaling Technology, 12683). After a 10 min PBS wash, secondary antibodies labeled with Alexafluor 488, 568, and 647 were applied for 1 h at room temperature. DAPI was added to the secondary antibody incubation to mark nuclei. Slides were then washed three times with PBS and then mounted with Prolong Diamond mounting medium. For histological analysis, sections were subsequently dipped in hematoxylin, then eosin, dehydrated in ethanol and xylene, and finally mounted using a xylene-based mounting medium. Images were collected using a Zeiss LSM 780 confocal microscope (Carl Zeiss) and prepared using Fiji (NIH).

[0193] For immunoblotting, organoids were flash frozen in liquid nitrogen and subsequently homogenized in RIPA buffer containing 1:100 Halt protease inhibitor (Thermo Fisher). The organoids were then washed twice with fresh medium and the liquid was collected by mouth pipetting using a glass capillary. Protein concentration was measured using the Bradford assay. Samples containing approximately 10 μg of protein were then prepared in NuPAGE LDS sample buffer 4× and DTT 1M and then heated at 95°C for 15 min. Protein samples and ladder were loaded onto a polyacrylamide gel and run at 90 mV for 2 h. Samples were transferred to a PVDF membrane (Immobilon) for 3 h at 4°C. Membrane The membranes were blocked with 5% milk in PBS-T and incubated with primary antibodies overnight at 4°C. After three washes with PBS, Alexafluor-conjugated secondary antibodies were added for 1 h at room temperature. Membranes were imaged using a Li-COR Odyssey CLx infrared imager.

[0194] Single-cell RNA sequencing and analysis Single cell dissociation was performed by first pooling two organoids for each condition: 55-day telencephalic organoids (sample 1), 53-day choroid plexus (sample 2), 27-day choroid plexus (sample 3) and 46-day choroid plexus (sample 4) in a 15 ml conical tube. Samples were incubated with 400 μg DNase I and 15 μM actinomycin D in 1 ml Accumax (Sigma, A7089) for 20 min at 37°C with gentle agitation. Sample tubes were tapped at 5 min intervals and finally pipetted up and down 10 times with a P1000 tip. Large clumps were allowed to settle, and the supernatant was collected, to which 100 μl FBS was added, and then filtered through a 35 μm filter tube (Corning, 352235). The sample was then spun at 300 × g for 5 min. Dead cells were then removed from the cell pellet using a dead cell removal kit and MACS columns (Miltenyi, 130-090-101) and spun again at 300×g for 5 min. Cells were resuspended in an appropriate volume of 0.04% BSA in PBS and loaded at 16,000 cells per well onto a 10X Chromium system (10X Genomics).

[0195] Single-cell RNA-seq libraries were performed using the 10X Genomics Chromium Single Cell 3' Library & Gel Beads Kit v3 (10X Genomics) workflow according to the manufacturer's instructions. A Chromium Controller was run following the protocol to create single cell gel beads in the emulsion mixture. The reverse transcriptase reaction and subsequent amplification were performed on a C1000 Touch thermal cycler (Biorad) and the quality of the libraries was checked using a 2100 Bioanalyzer Instrument (Agilent). Samples were pooled together and sequenced on a Novaseq sequencer (Illumina ) were sequenced in two lanes of an S1 flow cell.

[0196] The raw sequencing output was converted to standard fastq format by bcl2fastq and then subjected to CellRanger Count (version 3.1.0, 10X Genomics), which also performed read alignment to the GRCh38 human reference genome using STAR. The QC output revealed 10,327 cells with a mean of 39,973 reads per cell and a median UMI per cell of 4,660 for sample 1; 8,573 cells with a mean of 41,815 reads per cell and a median UMI per cell of 11,899 for sample 2; 5,347 cells with a mean of 67,938 reads per cell and a median UMI per cell of 16,252 for sample 3; and 8,603 cells with a mean of 45,030 reads per cell and a median UMI per cell of 9,927 for sample 4. The filtered feature barcode matrix for each sample was then analyzed using the Seurat v3 R package. This was further analyzed by first merging the matrices and then applying SCTransform to the whole cell. The method consisted of normalizing by the desired read depth, scaling the data, and finding variable features. Both mitochondrial mapping rate and cell cycle were regressed out during normalization to remove these confounding sources of variation. An ElbowPlot was used to guide the choice of dimensionality. Unbiased clustering was performed using PCA (4), followed by FindNeighbors, FindClusters, and UMAP dimensionality reduction visualization. The cluster was identified based on the analysis of 10 differentially expressed genes as well as known marker genes.

[0197] For comparison with in vivo data, we first created a subset of each individual cluster. For comparison with human developing brain scRNA-seq, expression matrices and metadata from Nowakowski et al. (3) were downloaded from UCSC Cell Browser and processed with cell cycle state regression and PCA clustering and UMAP visualization in Seurat v3 as above, resulting in 12 clusters identified based on top differentially expressed genes and known marker genes. Subsets were then created for each of these clusters. Normalized feature count data for each of the cluster subsets from organoids and human in vivo were averaged across all single cells within each cluster, followed by calculation of the Pearson correlation coefficient of the matrix and unbiased hierarchical clustering using the heatmap.2 function and Ward.D2 clustering with the Manhattan method.

[0198] For comparison with mouse embryo bulk RNA-seq data, raw feature counts were downloaded from NCBI GEO (GSE66312) (4) and TPMs were calculated, then converted to human gene names to remove duplicates and genes not present in humans. A cutoff TPM of 1 was set for at least one of the samples, and the average was then calculated for 1) all choroid plexus samples and 2) the sorted epithelial cell samples. Data were then log-transformed and merged with the organoid subset clusters (averaged as above). Genes not represented in all compared groups were removed, followed by scaling and principal component analysis.

[0199] Electron microscopy 2.5% glutaraldehyde and 2% paraformaldehyde (EM grade, Agar Scientific) in 0.1 M cacodylate buffer, pH 7.4 (CB) in glass vials. Organoids were fixed overnight at 4°C with 1% osmium tetroxide in CB. The next day, they were rinsed six times in CB and stored overnight at 4°C. Samples were then rinsed once more and post-fixed with 1% osmium tetroxide in CB for 1 h on ice and in the dark, washed five times over 1 h with distilled water, and dehydrated in an ascending ethanol series (30%, 50%, 70%, 90%, 100%) and then in propylene oxide for 10 min per step. Dehydrated samples were infiltrated and embedded in CY212 Araldite epoxy resin. Light gold 70 nm sections were cut from the embedded samples and counterstained with saturated aqueous uranyl acetate. Electron micrographs were taken on a FEI Tecnai Spirit TEM. The voltage was recorded at 80 kV.

[0200] Mass spectral data analysis Organoids were washed using PBS or fresh medium, and iCSF samples were collected by mouth pipetting with a glass microcapillary. Organoid fluid and medium were centrifuged at 500 g for 5 min to remove dead cells and debris, and subsequently analyzed by mass spectrometry. For mass spectrometry analysis, polyacrylamide gel slices (1–2 mm) containing purified proteins were prepared using a Janus liquid handling system (PerkinElmer, UK). Briefly, excised protein gel pieces were placed into wells of a 96-well microtiter plate, destained with 50% v / v acetonitrile and 50 mM ammonium bicarbonate, reduced with 10 mM DTT, and alkylated with 55 mM iodoacetamide. After alkylation, proteins were digested with 6 ng / μL endoprotease Asp-N (Promega, UK) overnight at 37 °C. The resulting peptides were then purified by centrifugation with 2% v / v formic acid, 2% The digest was extracted with v / v acetonitrile. The samples were analyzed by nanoscale capillary LC-MS / MS using a 5 μm C18 Acclaim PepMap100 (Dionex, San Jose, USA) with a flow rate of approximately 300 nL / min. Peptides were captured on a 100 μm × 20 mm nanoViper (Thermo Scientific Dionex, San Jose, USA) and then separated on a C18 Acclaim PepMap100 3 μm, 75 μm × 250 mm nanoViper (ThermoScientific Dionex, San Jose, USA). Peptides were eluted with a 60 min acetonitrile gradient (2% to 80%). The analytical column output was directly interfaced to a hybrid quadrupole-orbitrap mass spectrometer (Q-Exactive Plus Orbitrap, ThermoScientific, San Jose, USA) via a nanoflow electrospray ionization source. A resolution of 30,000 was used for the MS spectra, followed by data-dependent analysis using 10 MS / MS spectra. MS spectra were collected over an m / z range of 300-2000. MS / MS scans were collected using a threshold energy of 27 for higher energy collisional dissociation (HCD). The data were then analyzed using the Mascot search engine program (Matrix The LC-MS / MS data were searched against a protein database (UniProt KB) using the UniProt KB Gene Generator (UniProt KB Gene Generator, Science, UK) (5). Database search parameters were set as precursor tolerance 10 ppm and fragment ion mass tolerance 0.8 Da. One missed enzymatic cleavage was allowed and variable corrections were included for oxidized methionine, carbamidomethylcysteine, pyroglutamic acid, phosphorylated serine, threonine and tyrosine, and methylarginine. The MS / MS data were validated and emPAI values ​​were calculated using the Scaffold program (Proteome Software Inc., USA) (6). To compare corresponding proteins between samples of different species, only the highest emPAI value for each sample was considered as the peptide count for a given protein. Thus, for example, for human samples (organoids and human adult CSF), only the human TTR emPAI value was considered, whereas for bovine fetal CSF, the bovine TTR emPAI value was considered. For mouse embryonic CSF, the emPAI value and for mouse TTR emPAI value were considered, allowing the comparison of corresponding homologous proteins between samples despite differences in their accession numbers.

[0201] NMR sample preparation and analysis For NMR experiments, complete IDM+A medium without phenol red and 1:50 Geltrex (Gibco, A14132-02) for 2, 12, or 24 hours. The cells were incubated for 48 or 72 hours. Organoid medium and iCSF were collected and centrifuged at 500g for 5 minutes to remove debris. 1 H-NMR spectra were collected using a Bruker Ultrashield 400 Plus operated at 400.1 MHz. HOD suppression was used. hand 1 By collecting H-NMR data, 2 O / D 2 The samples analyzed consisted of a mixture of 0. Chemical shifts (δ) are given in ppm. 1 Conversion yields were determined by the relative integrals of signals in H-NMR spectra. Data analysis was performed using MestReNova (version 7.0) and GraphPad Prism (version 7.0b).

[0202] To compare in vitro and in vivo levels of small molecules in CSF, the in vivo unbound CSF-to-plasma ratio, K p,uu,CSF was used to calculate the unbound drug in plasma (C u,p ) to the unbound drug in CSF (C u,CSF ) was calculated (Equation A).

number

[0203] The amount of unbound drug in CSF and plasma was calculated as the total drug concentration (C p ) or (C CSF) and the fraction of unbound drug (f u,p ) or (f u,CSF ) (Equation B and Equation C). C u,p =C p f u,p (B) C u,CSF =C CSF f u,CSF (C)

[0204] C p , C CSF and f u,p was adopted from the literature (Table S2). However, since it is difficult to obtain large amounts of CSF, f u,CSF is unknown. Therefore, f u,CSF f u,p where drug-protein dissociation is assumed to be the same in plasma and CSF (Equation D) and the albumin CSF-to-plasma ratio (Q alb ) was set to 0.005 to correct for the reduced plasma protein content of CSF.

number

[0205] NMR measurements of in vitro solutions detected unbound drug, so the ratio (K m,uu,iCSF ) is the drug in the medium (C u,m ) in vitro CSF ​​against drugs (C u,iCSF ) (Equation E).

number

[0206] Example 1 As reported, cerebral organoids are characterized by intrinsic self-organization, and the most recent protocols have led to a predominantly forebrain identity (13, 14), which also includes the ChP epithelium (Figure 7A) (9, 13). Therefore, to study the development of human ChP, we established a protocol based on the cerebral organoid method to generate ChP in a reliable and reproducible manner.

[0207] In vitro derivation of ChP cells using the dorsalizing factor Bmp4 both alone ( 15 ) and in combination with the Wnt activator molecule CHIR ( 16 ) has been previously reported.

[0208] Therefore, to promote ChP fate in brain organoids, we pulsed Bmp4 and CHIR starting from day 10 of the improved brain organoid protocol (see Methods) (Figure 1A, Figure 7B, Figure 7C) (7, 9, 13). At day 14, non-oriented forebrain organoids developed large, circular neuroepithelial lobes, whereas in Bmp4 / CHIR-treated organoids, we observed more elongated neuroepithelial tissue (Figure 7B). This observation suggests that in vivo ChPs arise from the neuroepithelium at the dorsal midline, which then expands into the ventricles. This is consistent with the gradual elongation and expansion of the cavity (1, 17, 18). In comparison with forebrain organoids, which developed primarily large dorsal cortical identity lobes (Figure 1B, 1C), ChP organoids appeared to be almost entirely composed of ChP cuboidal epithelium (Figure 1B, 1C). Comparison of histological sections of ChP organoids at 40 days with human embryonic ChPs at 15 weeks post-gestation and ChPs from embryonic mouse brain at E18.5 showed that the human embryo samples and organoid tissues were highly similar in terms of complexity and organization (Figure 1D).

[0209] In vivo, ChP epithelium initially develops as a pseudostratified epithelium, followed by an intermediate columnar stage, and then matures into a highly folded cuboidal epithelium (1, 18, 19). To confirm tissue specificity, we performed staining for the ChP marker TTR, the neural stem cell marker Sox2, and the tight junction marker ZO1 at early and later time points (Figure 1E, Figure 1F). ChP organoids treated with Bmp4 and CHIR developed pseudostratified neuroepithelium with TTR-positive areas by day 28 (Figure 1E). By day 39, treated organoids developed a more columnar, polarized ChP epithelium with more concentrated TTR immunostaining, relatively strong ZO1 expression at cell-cell junctions, and sparse Sox2 immunostaining (Figure 1F). Quantification of TTR-positive areas showed reproducible concentration in treated organoids compared to untreated controls (Figure 1G). Taken together, these data demonstrate the reliable and reproducible generation of ChP tissues in vitro from various human pluripotent stem cell lines and by two different seeding methods (Figures 7C-G).

[0210] ChP expresses the highest levels of the channel protein, chloride intracellular channel (CLIC6), in the brain (20). We were able to detect CLIC6 in ChP organoid epithelium compared to control untreated organoids by both immunohistochemistry (Figure 2A) and immunoblot (Figure 2B-C). In parallel, lower levels of the forebrain marker Foxg1 were detected in treated organoids compared to controls (Figure 2B-C). Cortical-specific Tbr2-positive intermediate progenitor cells and HuC / D-positive neurons were also strongly reduced in early ChP organoids compared to controls and were almost completely absent in mature ChP organoids (Figure 8A).

[0211] ChP contains both epithelial and stromal components: a polarized epithelium faces the ventricular lumen at the apical side and surrounds an interstitial core exposed to fenestrated capillaries. To better characterize the different cell populations present in ChP organoids, we sampled two organoids from three separate batches of ChP organoids at different maturation stages and two untreated telencephalic organoids as controls and performed single-cell RNA sequencing (scRNA-seq) (Figure 2F, Figure 2G). Combined analysis identified the expected clusters of cells expressing markers of neurons and neuronal precursors in untreated organoids, while immature and mature ChP identities were enriched in ChP organoids (Figure 2F). Unbiased analysis revealed that treated organoids consistently and progressively enriched ChP populations over time (Figure 2G). Older treated organoids showed a larger component of ChP mature epithelial cells as well as an accumulation of stromal cells compared to earlier stage organoids and untreated controls (Figure 2G). Consistent with our previous staining, we confirmed the expression of CLIC6 and other specific ChP markers, such as the serotonin receptor HRT2C (21) (Figure 2H). As expected, immature ChP / hem clusters of cells expressed higher levels of early regulators involved in ChP development, such as the homeobox proteins MSX1, OTX2, R-spondin 3 (RSPO3) and PAX6 (Figure 2H, Figure 2I). Mature ChP cell populations expressed higher levels of TTR, carbonic anhydrase 2 and 12 (CA2, CA12), nucleoside diphosphate kinase homolog 5 (NME5), inwardly rectifying potassium channel 13 (KCNJ13) and the epithelial marker keratin 18 (Krt18) (Figure 2I). More mature Krt18-positive cells A maturation gradient in ChP epithelium in vivo has been reported previously (21), which is located distal to the ventricles. Krt18 was accumulated in more mature ChP organoids compared to early immature ones (Figure 2D). To investigate the stromal component of ChP in our system, we examined the expression of DLK1 (delta-like noncanonical notch ligand 1), a gene expressed in ChP mesenchyme (21), by immunohistochemistry (Figure 2E). Expression of DLK1 and other ChP stromal proteins (lumican, LUM, and decorin, DCN) was detected in the extent of the organoids and epithelium surrounding the ChP (Figure 2E, Figure 8B). Consistent with these results, the ChP stromal population detected by scRNA-seq expressed high levels of DCN, LUM, and DLK1 (Figure 2I) as well as the extracellular matrix component collagen alpha-1 chain 1 (COL1A1) (Figure 2H). These data suggest that in vitro derived ChP organoids generate both epithelial and stromal components.

[0212] Next, we sought to identify similarities between our in vitro model and in vivo ChP tissue. We performed unbiased clustering and principal component analysis (PCA) on previously published datasets of mouse ChP tissue (1) and developing human brain (2) (Figure 3A-D). First, we performed PCA between our identified organoid clusters and RNAseq data from in vivo E18.5 mouse embryonic whole ChPs and isolated epithelial ChP cells (4). We could observe the closest proximity between our mature ChP clusters and ChPs from in vivo samples compared to other identified clusters (Figure 3A). We then performed correlation analysis between organoid clusters and those of human developing brain in vivo (22), revealing high correlation between organoid and in vivo ChP clusters and between organoid and in vivo stroma clusters (Figure 3B). Further unbiased hierarchical clustering revealed that organoid mature and immature ChPs clustered together with in vivo ChPs, and organoid ChP stroma clustered with in vivo stroma identity (Figure 3C). To further investigate whether our system can better model human ChPs in particular, we then compared organoid mature ChP clusters with both human and mouse in vivo (Figure 3D), revealing higher correlation with human ChPs compared to mouse (Figure 3D). Finally, examination of specific regional ChP markers (4, 24) revealed that choroid plexus organoids were of lateral ventricular identity rather than third or fourth ventricle identity (Figure 3E), consistent with their telencephalic origin. Overall, these data demonstrate that the ChP epithelial and stromal composition of the organoids appears to recapitulate the cellular composition and genetic architecture of human ChP in vivo.

[0213] To investigate the degree of maturation of ChP organoids, we focused on previously described ChP maturation markers. We could observe the presence of cilia markers, which have been suggested to be expressed during ChP epithelial maturation (3), as well as a marker of more mature ChP epithelium, aquaporin 1 (AQP1). We could detect the accumulation of cilia genes such as DYNLRB2 and FOXJ1 in mature ChP clusters, as well as the accumulation of AQP1 (Figure 3F). Staining further revealed the presence of CCDC67 and FOXJ1, both regulators of ciliary development, as well as the cilia protein ARL13B, which stained the apical cilia tufts in ChP epithelium (Figure 3G). AQP1 staining also confirmed the presence of this more mature marker, which shows a localization to the apical side of the epithelium, as in vivo (Figure 3H). The ChP epithelium is a highly efficient secretory machinery (23) with numerous microvilli, motile cilia, and a dense network of cytoplasmic vesicles that enhance its surface area at the apical side. To further investigate whether ChP organoids recapitulate these fundamental ultrastructural features, we performed EM imaging. We found primary cilia, extensive apically located microvilli, tight junctions between cells, and a number of cytoplasmic vesicles. We observed junctions, multivesicular bodies and numerous extracellular vesicles (Figure 3I; indicated by arrows). Consistent with its role in brain lipid metabolism, we also observed accumulation of lipid droplets and lipoproteins (ApoE, clusterin / ApoJ and phospholipid transfer protein PLTP) (Figure 3J). These features, together with the loss of actively cycling cell cycle marker phosphohistone H3 (PH3)-positive cells (Figure 3K, Figure 2D), suggest a fully mature glandular epithelium in ChP organoids.

[0214] Next, we asked whether ChP organoids could develop a tight barrier by examining the expression of tight junction markers such as claudins and occludin (25, 26), which seal the intercellular gaps between cells of the ChP epithelial barrier. scRNA-seq revealed the presence of several claudins (Figure 4A) as well as other tight junction components occludin (OCLN), ZO1 (TJP1), ZO2 (TJP2), and the PDZ proteins PATJ (INADL) and MPDZ (Figure 4B). Staining revealed the apical localization of claudins 1, 3, 4, and 5 in the polarized epithelium of ChP organoids, confirming their enriched expression (Figure 4C). Low levels of claudin 2 (Figure 11A) and the presence of OCLN (Figure 11B) were also observed in the ChP organoid epithelium. Finally, to directly assess the barrier function of the ChP epithelium, we applied fluorescently labeled dextrans of various molecular weights (70, 10, and 3-5 kDa) and examined their penetration into the organoids. After 2 h of incubation, no obvious leakage of 10 kDa Alexa-647-labeled dextran was observed inside the organoids (Figure 11C). The fluorescence intensity of the medium and internal fluid collected after 2 h of incubation with 70 kDa, 10 kDa, and 3–5 kDa labeled dextrans confirmed that these molecules were completely excluded from the organoids (Figure S11D).

[0215] A striking feature of ChP organoids was the later development of large fluid-filled compartments or cysts containing colorless liquid, which were rarely or never present in untreated forebrain organoids (Figure 4D, Figure 9A-9B). We found that these compartments could be completely isolated from the medium and maintained by continuing to add dissolved Matrigel to the medium. We observed that the same cuboidal epithelium surrounded these compartments and exhibited a polar orientation, with the apical markers Aqp1 and ZO1 on the luminal side toward the liquid (Figure 4D).

[0216] To investigate the composition of this fluid, we performed mass spectrometry analysis to compare in vitro organoid CSF-like fluid (iCSF) (3 batches of H9, 1 batch of H1, and 1 batch of iPSC IMR-90) with 3 different in vivo samples (human adult telencephalic CSF pooled from 3 healthy donors, mouse embryonic CSF at E13.5, and fetal bovine CSF) and culture medium. We detected a total of 248 abundant proteins in organoid iCSF, of which 199 were in common with the in vivo CSF ​​samples (Figure 10A). Gene ontology analysis revealed that the GO:CC categories "extracellular vesicles" and "extracellular space" and the GO:BP categories "extracellular transport" and "secretion from cells" were enriched in the organoid fluid proteome (Figure 5A). Insulin-like growth factors, particularly IGF2, are secreted by ChPs and regulate cortical progenitor cell proliferation in the developing CSF. (2) Consistent with a role for IGFs in the developing CSF, the REAC category “regulation of insulin-like growth factors” was also highly enriched in organoid iCSF.

[0217] We next focused on proteins detected in at least two organoid iCSF samples to exclude technical artifacts, and then we looked for the most abundant proteins with emPAI reported values ​​of 1 based on the number of peptides observed. Of these 83 abundant proteins detected in organoid iCSF, 80 Some of the proteins were also detected in the in vivo samples, further pointing out their high similarity (Fig. 5B, Fig. S10C). Among these proteins, we detected several biomarkers, such as clusterin (CLU), phospholipid transfer protein (PLTP) and apolipoprotein E (APOE) (Fig. 5B, Supplementary Table 1). Many of the proteins detected in iCSF, such as insulin-like growth factor binding protein 7 (IGFBP7), serpin family F member 1 (SERPINF1), Niemann-Pick disease type C2 protein (NPC2) and retinol binding protein 1, could also be detected by scRNA-seq ChP clusters (Fig. 5C, Fig. 5D), further confirming their production. Some proteins were only present in human organoids and adult human CSF samples, suggesting a potential human-specific secretion (Fig. 5E). We also detected several developmental stage-specific CSF proteins not found in adult human samples, including insulin-like growth factor 2 (IGF2), IGFBP7, and follistatin-like protein 1 (FSTL1), indicating that iCSF secreted by ChP organoids at least partially retains the developmental stage characteristics of human CSF (Figure 5E). IGF2 levels in organoid fluid were verified by immunoblot (Figure 5G, Figure 8C), and immunohistochemistry revealed its presence in ChP epithelium (Figure 5H). Consistent with the unique role of ChP in the transport of folate and vitamin C, both of which are crucial for brain homeostasis and function (27, 28), we detected the accumulation of specific transporters SLC23A2 (vitamin C) and SLC46A2 (folate) involved in the transport of these nutrients in ChP epithelial clusters (Figure 5D).

[0218] We next asked at which stage iCSF from organoids best fits by further comparing with a previously published proteomic dataset of human embryonic Carnegie developmental stage 20 CSF (29). We could observe that organoid iCSF overlapped more with adult CSF, with 121 proteins in common compared to 51 proteins shared between iCSF and embryonic in vivo CSF ​​(Figure 5E), indicating that iCSF is perhaps more similar to adult CSF, but still retains some developmental stage features.

[0219] Overall, there was very good agreement between the in vitro and in vivo samples. However, to fully confirm the in vivo similarity, we further investigated the proteins with abnormal distribution. First, the vast majority of proteins detected were absent in the medium, pointing to a highly selective barrier, while proteomic analysis revealed that 13 of the 14 abundant proteins in the medium were also present in the organoid iCSF (Figure 10D). Importantly, many of these were also detected in the in vivo samples, including proteins such as albumin (ALB) and transferrin (TF) that actively transport across the ChP epithelium. Not detected in vivo are proteins provided by Matrigel, including some laminins. Second, there were several proteins reproducibly detected in the in vivo samples but not in the organoid iCSF, which may be factors that cause organoids not to be generated correctly, and this justifies further investigation. However, we found that proteins detected only in in vivo CSF ​​samples, but not in organoid iCSF, showed enrichment for GO:CC "blood microparticles", GO:BP "platelet degranulation" and KEGG: "complement and coagulation cascade" (Figure 10B, Figure 10E, Figure 10F). This could be explained by the fact that contamination with peripheral blood and bone marrow often occurs in the invasive procedure of lumbar puncture (spinal tap) CSF collection. Thus, one advantage of the organoid system is that ChP organoids are devoid of vascular components. Thus, we expect this fluid to be exclusively ChP secretome. Taken together, these findings suggest that 1. ChP organoids develop self-supporting compartments that can be distinguished from the surrounding medium by a tight epithelial barrier; 2. ChP organoids express human developmental stage-specific CSF proteins without blood contamination; These results suggest that the endothelial cells actively secrete accumulated CSF-like fluid.

[0220] As part of its selective barrier function, the ChP epithelium is also highly selective for small molecules, including therapeutic drugs. Therefore, to test such selective permeability to small molecules, we applied various therapeutically relevant small molecules and assayed their permeability by NMR analysis of organoid iCSF. As proof of principle, we tested the permeability of the barrier to dopamine (dopa) and its precursor, levodopa (L-dopa), since they are highly similar molecules with very different permeabilities in vivo and such specificity has never been reported before in any in vitro model of the BBB. While dopa does not enter the brain in vivo, it is well established that L-dopa is actively transported into the CSF by the LAT-1 transporter (30-33) and is therefore given as a therapeutic agent in dopamine replacement therapy for Parkinson's disease patients. We incubated organoids with dopa and L-dopa in the presence of carbidopa (34, 35), a small molecule that prevents the conversion of L-dopa to dopa. After 2 hours, we could detect the presence of both L-dopa and dopa in the medium, but only L-dopa was detectable in the iCSF, consistent with the in vivo characteristics of the CNS barrier (Figure 6A, Figure 11E). The L-dopa iCSF / medium ratio was consistently higher than the dopa iCSF / medium ratio, suggesting that our model exhibited the same selectivity for small molecules as in vivo (Figure 6A).

[0221] These findings suggest that there may be an authentic expression of major transporters in the blood-CNS barrier. Indeed, we were able to detect the expression of the transporter LAT-1 on the apical side of the ChP organoid epithelium (Fig. 6D, Fig. 8C), explaining the authentic transport of L-dopa seen in our permeability assay. We also stained for the well-known efflux pump P-glycoprotein 1 (Pgp or multidrug resistance protein 1, MDR1) (36, 37), which prevents drugs from entering the brain by an ATP-dependent mechanism (Fig. 6D). We detected apical and subapical expression of Pgp in the ChP epithelium, which appears to be localized in intracellular vesicles (Fig. 6D). The localization of Pgp in ChP is not well established (38, 39), however, it has been reported to play a role in pumping molecules from the CSF to the blood (38, 40). Further important efflux transporters in ChP are MRP1 and MRP4, which prevent toxic compounds and unwanted signals from reaching the CSF (38, 41). MRP1 was localized in both the apical and basal parts of ChP epithelium at 40 days in culture (Fig. 6D, Fig. 8C), whereas MRP4 was expressed apically in ChP epithelium (Fig. 6D). These results suggest that in vitro generated ChP epithelium endogenously expresses transport and efflux pumps that are critical for the proper functioning of B-CSF-B in the human brain.

[0222] Next, we tested whether this system could quantitatively predict drug permeability. To this end, we performed similar permeability experiments to test bupropionil (42), an antidepressant known to readily cross the BBB, and two chemotherapeutic compounds methotrexate and vincristine (43, 44), which poorly cross the BBB. As expected, bupropionil was readily detectable in the iCSF after 2 h, whereas methotrexate and vincristine were completely excluded from the iCSF (Figure 6B). Most importantly, we found an extremely high correlation between the in vitro iCSF / medium ratios and the in vivo CSF / plasma ratios reported in the literature for the same drugs (R2 = 0.9921). Not only that, but the actual values ​​corresponded remarkably well (as indicated by the slope of 1.004), demonstrating that this in vitro system can qualitatively and quantitatively reproduce the drug permeability reported in vivo (Figure 6E).

[0223] These results suggest that this ChP organoid system may be used to model and predict the CNS permeability of unknown drugs. To test this theory, we focused on cefin1 (45), a novel inhibitor of the regulatory subunit of protein phosphatase 1, PPP1R15A, which has been shown to cross the BBB and have a protective CNS role against protein misfolding in a mouse model of Charcot-Marie-Tooth disease type 1B. No preclinical or clinical data in humans is currently available for this molecule, but a phase I clinical trial is ongoing, so any additional human in vitro data may be informative. Using the same experimental conditions as previously described, cefin1 was detectable in iCSF after 2 hours of incubation, indicating that this compound can also cross the human CNS barrier (Figure 6C). Notably, however, permeability in the human organoid model was much lower than that described in the mouse model, suggesting that higher doses may be required to achieve the same CNS levels in humans.

[0224] Problems related to the pharmacokinetic profile of drugs are the cause of failure of many clinical trials (46, 47). One extreme example involved the compound BIA-10-2474, a fatty acid amide hydrolase inhibitor that was in development for the treatment of several pathologies, including chronic pain and multiple sclerosis (48, 49). Unfortunately, the phase I clinical trial was abruptly halted after six study participants developed severe neurotoxicity, one of which died (49, 50). An investigation conducted by the French Ministry of Health suggested several possible explanations, one of which was the accumulation of toxic drugs in the brain, which was not evident in any of the animal models tested (49-51). However, the exact cause remains unclear, as further studies were halted. Given the failure to detect such adverse effects in animal models, we sought to test this accumulation hypothesis by examining whether human ChP organoids might be able to more accurately predict human CNS permeability. We compared the pharmacokinetic profile of BIA-10-2474 with that of bupropionil, a safe compound that readily crosses epithelial barriers but has not been shown to exhibit such toxic accumulation. Similar to bupropionil, BIA-10-2474 was able to cross the ChP epithelial barrier after 2 hours of incubation (Figure 6F). However, BIA-10-2474 continued to accumulate in iCSF (Figure 6G), compared to bupropionil, which stabilized to baseline levels after 24 hours. These data are consistent with the theory that BIA-10-2474 may have accumulated in the brains of study participants, which may explain why the drug failed in clinical trials. In summary, our findings suggest that the present organoid system can be used as a human in vitro preclinical model to quantitatively predict not only the permeability of unknown compounds, but also their kinetics over time (Figure 6H).

[0225] In conclusion, ChP organoids allow unprecedented and reliable study of the development and function of human ChP, a poorly studied organ that is receiving increasing attention due to its important role in development and diseases such as neurodegeneration.

[0226] Supplementary Table 1. ChP organoids secrete human disease-associated biomarkers. Table showing biomarkers detected in iCSF (31 of the 50 most abundant iCSF proteins are shown), the diseases or pathologies in which those biomarker levels are altered, and the relevant literature. Asterisks indicate proteins that are also detected in the medium (8-59).

[0227] Supplementary Table 2. Timepoint permeability experiments. Table showing cell lines, batch numbers, and dates of iCSF harvest (DIV) of relevant drugs tested on ChP organoids shown in Figure 6.

[0228] Supplementary Table 3. iCSF for timepoint proteomics. Table showing cell lines, batch creation dates and iCSF harvest dates (DIV) for samples used in the proteomic analysis shown in Figure 5. Asterisks indicate samples that were pooled together.

[0229] Supplementary Table 4. In vivo CSF ​​for timepoint proteomics. Table showing the in vivo sample types and sample sizes used for the proteomic analysis shown in Figure 5. Asterisks indicate samples that were pooled together.

[0230] Supplementary Table 5. In vivo and in vitro data on drug CSF levels. Table showing measured and calculated ratios (K) (60-68) of unbound small molecule in CSF and plasma (in vivo) or medium (in vitro).

[0231] [Table 1]

[0232] [Table 2]

[0233] [Table 3]

[0234] [Table 4]

[0235] [Table 5]

[0236] All publications mentioned in the above specification are incorporated herein by reference.Various improvements and modifications of the disclosed products, uses and methods of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention.Although the present invention has been disclosed in connection with specific preferred embodiments, it should be understood that the present invention as claimed should not be unduly limited to such specific embodiments.Indeed, various modifications of the disclosed aspects of the present invention that are obvious to those skilled in the art are intended to be within the scope of the following claims.

[0237] References for Example 1 1. Lun, MP, Monuki, ES and Lehtinen, MK (2015) Development and functions of the choroid plexus-cerebrospinal fluid system. Nat. Rev. Neurosci., 16, 445-457. 2. Lehtinen, MK and Walsh, CA (2011) Neurogenesis at the Brain-Cerebrospinal Fluid Interface. Annu. Rev. Cell Dev. Biol., 27, 653-679. 3. Silva-Vargas, V., Maldonado-Soto, A. R., Mizrak, D., Codega, P. and Doetsch, F. (2016) Age-Dependent Niche Signals from the Choroid Plexus Regulate Adult Neural Stem Cells. Cell Stem Cell, 19, 643-652. 4. Lun, M. P., Johnson, M. B., Broadbelt, K. G., Watanabe, M., Kang, Y.-j., Chau, K. F., Springel, M. W., Malesz, A., Sousa, A. M. M., Pletikos, M., et al. (2015) SpatiallyHeterogeneous Choroid Plexus Transcriptomes Encode Positional Identity and Contribute to Regional CSF Production. J. Neurosci., 35, 4903-4916. 5. Ghersi-Egea, J. F., Strazielle, N., Catala, M., Silva-Vargas, V., Doetsch, F. and Engelhardt, B. (2018) Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in Health and disease. Acta Neuropathol., 135, 337-361. 6. Redzic, Z. (2011) Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: Similarities and differences. Fluids Barriers CNS, 8, 3. 7. Lancaster, M. and Knoblich, J. A. (2014) Generation of cerebral organoids from Human pluripotent stem cells. Nat. Protoc., 9, 2329-2340. 8. Camp, J. G., Badsha, F., Florio, M., Kanton, S., Gerber, T., Wilsch-Braeuninger, M., Lewitus, E., Sykes, A., Hevers, W., Lancaster, M., et al. (2015) Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc. Natl. Acad. Sci. U. S. A., 112, 15672-7. 9. Lancaster, M. A., Renner, M., Martin, C., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P. and Knoblich, J. A. (2013) Cerebral organoids model Human brain development and microcephaly. Nature, 501, 373-379. 10. Quadrato, G., Brown, J. and Arlotta, P. (2016) The promises and challenges of Human brain organoids as models of neuropsychiatric disease. Nat. Med., 22, 1220-1228. 11. Quadrato, G., Nguyen, T., Macosko, E. Z., Sherwood, J. L., Min Yang, S., Berger, D. R., Maria, N., Scholvin, J., Goldman, M., Kinney, J. P., et al. (2017) Cell diversity and network dynamics in photosensitive Human brain organoids. Nature, 545, 48-53. 12. Evolution, H. B., Pollen, A. A., Bhaduri, A., Andrews, M. G., Haussler, D., Eichler, E. E., Kriegstein, A. R., Pollen, A. A., Bhaduri, A., Andrews, M. G., et al. (2019) Establishing Cerebral Organoids as Models of Article Establishing Cerebral Organoids as Models of Human-Specific Brain Evolution. Cell, 176, 743-756. e17. 13. Lancaster, M. A., Corsini, N. S., Wolfinger, S., Gustafson, E. H., Phillips, A. W., Burkard, T. R., Otani, T., Livesey, F. J. and Knoblich, J. A. (2017) Guided self-organization and cortical plate formation in Human brain organoids. Nat. Biotechnol., 35, 659-666. 14. Giandomenico, S. L., Mierau, S. B., Gibbons, G. M., Wenger, L. M. D., Masullo, L., Sit, T., Sutcliffe, M., Boulanger, J., Tripodi, M., Derivery, E., et al. (2019) Cerebral organoids at the air-liquid interface generate diverse nerve tracts with functional output. Nat. Neurosci., 22, 669-679. 15. Watanabe, M., Kang, Y.-J., Davies, L. M., Meghpara, S., Lau, K., Chung, C.-Y., Kathiriya, J., Hadjantonakis, A.-K. and Monuki, E. S. (2012) BMP4 Sufficiency to Induce Choroid Plexus Epithelial Fate from Embryonic Stem Cell-Derived Neuroepithelial Progenitors. J. Neurosci., 32, 15934-15945. 16. Sakaguchi, H., Kadoshima, T., Soen, M., Narii, N., Ishida, Y., Ohgushi, M., Takahashi, J., Eiraku, M. and Sasai, Y. (2015) Generation of functional Hippocampal neurons from self-organizing Human embryonic stem cell-derived dorsomedial telencephalic tissue. Nat. Commun., 6, 1-11. 17. Currle, D. S., Cheng, X., Hsu, C. and Monuki, E. S. (2005) Direct and indirect roles of CNS dorsal midline cells in choroid plexus epithelia formation. Development, 132, 3549-3559. 18. Liddelow, S. A. (2015) Development of the choroid plexus and blood-CSF barrier. Front. Neurosci., 9, 1-13. 19. Lehtinen, M. K., Bjornsson, C. S., Dymecki, S. M., Gilbertson, R. J., Holtzman, D. M. and Monuki, E. S. (2013) The Choroid Plexus and Cerebrospinal Fluid: Emerging Roles in Development, Disease, and Therapy. J. Neurosci., 33, 17553-17559. 20. Sathyanesan, M., Girgenti, M. J., Banasr, M., Stone, K., Bruce, C., Guilchicek, E., Nairn, A. and Williams, K. (2012) A molecular characterization of the choroid plexus and stress-induced gene regulation. Transl. Psychiatry, 2, e139-9. 21. Dani, N., Mccabe, C., Cui, J., Shipley, F. B. and Jang, A. (2019) A cellular and spatial map of the choroid plexus across brain ventricles and ages. bioRxiv. 22. Nowakowski , TJ , Bhaduri , A , Pollen , AA , Alvarado , B , Mostajo-Radji , MA , Di Lullo , E , Haeussler , M , Sandoval-Espinosa , C , Liu , SJ , Velmeshev , D , et al. (2017) Spatiotemporal Gene Expression Trajectories Reveal Developmental Hierarchies of the Human Cortex. Science (80-.)., 358, 1318-1323. 23. Damkier , HH , Brown , PD and Praetorius , J. ( 2013 ) Cerebrospinal Fluid Secretion by the Choroid Plexus . Physiol. Rev., 93, 1847-1892. 24. Neil Dani1*, RebeccaH. Herbst2, 3*, NaomiHabib2, 4*, Head1, J., Dionne2, D., Nguyen2 , L. , McCabe2 , C. , Cui1 , J. , Frederick B. Shipley1 , 5 , Jang1 , A. , et al. (2019) A cellular and spatial map of the choroid plexus across brain ventricles and ages. https: / / doi.org / 10.1103 / PhysRevLett.101.111101 , Google Scholar Crossref , CAS 25. Steinemann, A., Galm, I., Chip, S., Nitsch, C. and Reese, T. (2016). the Mouse from Early Development and into Adulthood While Claudin-5 is Restricted to Endothelial Cells. 10, 1-10. 26. Wolburg, H., Wolburg-buchholz, K., Liebner, S. and Engelhardt, B. (2001) Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. 307, 77-80. 27. Wollack, J. B., Makori, B., Ahlawat, S., Koneru, R., Picinich, S. C., Smith, A., Goldman, I. D., Qiu, A., Cole, P. D., Glod, J., et al. (2008) Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. 10.1111 / j.1471-4159. 2007. 05095.x. 28. Ulloa, V., Saldivia, N., Ferrada, L., Salazar, K., Martinez, F., Silva-a, C., Magdalena, R., Oviedo, M. J., Montecinos, H., Torres-vergara, P., et al. (2019) Basal Sodium-Dependent Vitamin C Transporter 2 polarization in choroid plexus explant cells in normal or scorbutic conditions. 10. 1038 / s41598-019-50772-2. 29. Zappaterra, M. D., Lisgo, S. N., Lindsay, S., Gygi, S. P., Walsh, C. A. and Ballif, B. A. (2007) A comparative proteomic analysis ofHuman and rat embryonic cerebrospinal fluid. J. Proteome Res., 6, 3537-3548. 30. Duelli, R., Enerson, B. E., Gerhart, D. Z. and Drewes, L. R. (2000) Expression of Large Amino Acid Transporter LA T 1 in Rat Brain Endothelium. 37764, 1557-1562. 31. Dickens, D., Chiduza, G. N., Wright, G. S. A., Pirmohamed, M., Antonyuk, S. V andHasnain, S. S. (2017) Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Nat. Publ. Gr., 1, 1-13. 32. Uchino, H., Kanai, Y., Kim, D. O. K., Wempe, M. F., Chairoungdua, A., Morimoto, E., Anders, M. W. and Endou, H. (2002) Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition. Mol. Pharmacol., 61, 729-737. 33. Dolgodilina, E., Imobersteg, S., Laczko, E., Welt, T., Verrey, F. and Makrides, V. (2016) Brain interstitial fluid glutamineHomeostasis is controlled by blood-brain barrier SLC7A5 / LAT1 amino acid transporter. JCBFM, 36, 1929-1941. 34. Zhu, H., Lemos, H., Bhatt, B., Islam, B. N., Singh, A., Gurav, A., Huang, L., Browning, D. D., Mellor, A., Fulzele, S., et al. (2017) Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity. PLoS One, 12, e0183484. 35. Durso, R., Evans, J. E., Josephs, E., Szabo, G., Evans, B., Fernandez, H. H. and Browne, T. R. (2000) Variable Absorption of Carbidopa Affects Both Peripher al and Central Levodopa Metabolism. J Clin Pharmacol, 40, 854-860. 36. Assema, D. M. E. Van, Lubberink, M., Boellaard, R., Schuit, R. C., Windhorst, A. D., Scheltens, P., Lammertsma, A. A. and Berckel, B. N. M. Van (2012) P-Glycoprotein Function at the Blood-Brain Barrier: Effects of Age and Gender. Mol. Imaging Biol., 14, 771-776. 37. Schinkel, A. H. (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev., 36, 179-194. 38. Vallabhaneni V. Rao, Julie L. Dahlheimer, Mark E. Bardgett, Abraham Z. Snyder, Rick A. Finch, Alan C. Sartorelli, D. P.-W. (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. 96, 3900-3905. 39. Nagaya, Y., Nozaki, Y., Takenaka, O., Watari, R., Kusano, K., Yoshimura, T. and Kusuhara, H. (2016) Drug Metabolism and Pharmacokinetics Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a (- / -. Drug Metab. Pharmacokinet., 31, 57-66. 40. Ek, C. J., Wong, A., Liddelow, S. A., Johansson, P. A., Dziegielewska, K. M. and Saunders, N. R. (2010) Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. Toxicol. Lett., 197, 51-59. 41. Uchida, Y., Zhang, Z., Tachikawa, M. and Terasaki, T. (2015) Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with aHuman specimen. J. Neurochem., 134, 1104-1115. 42. Summerfield, S. G., Zhang, Y. and Liu, H. (2016) Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier s. J. Pharmacol. Exp. Ther., 358, 294-305. 43. Angelov, L., Doolittle, N. D., Kraemer, D. F., Siegal, T., Barnett, G. H., Peereboom, D. M., Stevens, G., Mcgregor, J., Jahnke, K., Lacy, C. A., et al. (2009) Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience. J. Clin. Oncol., 27, 3503-3509. 44. Zylber-Katz, E., Gomori, J. M., Schwartz, A., Lossos, A., Bokstein, F. and Siegal, T. (2000) Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clin. Pharmacol. Ther., 67, 631-641. 45. Das, I., Krzyzosiak, A., Schneider, K., Wrabetz, L., Antonio, M. D., Barry, N., Sigurdardottir, A. and Bertolotti, A. (2015) Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. 348, 239-243. 46. Wong, C. H. I. H., Siah, K. W. E. I. and Lo, A. W. (2019) Estimation of clinical trial success rates and related. Biostatistics, 20, 273-286. 47. Cummings, J. L., Morstorf, T. and Zhong, K. (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers. Res. Ther., 6, 1-7. 48. Otrubova, K., Ezzili, C. and Boger, D. L. (2012) The Discovery and Development of Inhibitors of Fatty Acid AmideHydrolase (FAAH). Bioorg. Med. Chem. Lett.,21, 4674-4685. 49. Kaur, R., Sidhu, P. and Singh, S. (2016) What failed BIA 10-2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials. J. Pharmacol. Pharmacother., 7, 120-126. 50. Butler, D. and Callaway, E. (2016) Scientists in the dark after fatal French clinical trial. Nature, 529, 236-264. 51. Bird, S. M., Bailey, R. A., Sl, M. and Senn, S. (2017) Statistical issues in first-in-human studies on BIA 10-2474: neglected comparison of protocol against practice. Pharm Stat., 16, 100-106. 52. Nicolas, J.-M. (2015) Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. 53. Dobson, P. D. and Kell, D. B. (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? 7

[0238] References related to materials and methods and supplementary tables 1. Lancaster, M. and Knoblich, J. A. (2014) Generation of cerebral organoids from Human pluripotent stem cells. Nat. Protoc., 9, 2329-2340. 2. Lancaster, MA, Corsini, NS, Wolfinger, S, Gustafson, EH, Phillips, AW, Burkard, TR, Otani, T, Livesey, FJ and Knoblich, JA (2017) Guided self-organization and cortical plate formation in human brain organoids. Nat. Biotechnol., 35, 659–666. 3. Nowakowski , TJ , Bhaduri , A , Pollen , AA , Alvarado , B , Mostajo-radji , MA , Lullo , E , Di , Haeussler , M , Sandoval-Espinosa , C , Liu , SJ , Velmeshev , 2002 . D., et al. (2017) Spatiotemporal Gene Expression Trajectories Reveal Developmental Hierarchies of theHuman Cortex. 1323 , 1318–1323 . 4. Lun, MP, Johnson, MB, Broadbelt, KG, Watanabe, M, Kang, Y-J, Chau, KF, Springel, MW, Malesz, A, Sousa, AMM, Pletikos, M, et al. (2015) SpatiallyHeterogeneous Choroid Plexus Transcriptomes Encode Positional Identity and Contribute to Regional CSF Production. J. Neurosci., 35, 4903–4916. 5. Pappin, D. J. C., Creasy, D. M., Cottrell, J. S. and Perkins, D. N. (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis, 20, 3551-67. 6. Keller, A., Nesvizhskii, A. I., Kolker, E. and Aebersold, R. (2002) Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS / MS and Database Search. Anal. Chem.,74, 5383-5392. 7. Friden, M., Winiwarter, S., Jerndal, G., Bengtsson, O., Hong, W., Bredberg, U., Hammarlund-Udenaes, M. and Antonsson, M. (2009) Structure-brain exposure relationships in rat andHuman using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J. Med. Chem., 52, 6233-6243. 8. Costa, M., Horrillo, R., Ortiz, A. M., Perez, A., Mestre, A., Ruiz, A., Boada, M. and Grancha, S. (2018) Increased Albumin Oxidation in Cerebrospinal Fluid and Plasma from Alzheimer’s Disease Patients. J. Alzheimer’s Dis., 63, 1395-1404. 9. Ghasemzadeh, N., Nyberg, F. andHjerten, S. (2008) Original PaperHighly selective artificial gel antibodies for detection and quantification of biomarkers in clinical samples. II. Albumin in body fluids of patients with neurological disorders. J Sep Sci, 31, 3954-3958. 10. Bonham, L. W., Geier, E. G., Steele, N. Z. R., Holland, D., Miller, B. L., Dale, A. M., Desikan, R. S. and Yokoyama, J. S. (2018) Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer’s Disease Pathology and Shows Differential Expression in Transgenic Mice. Front. Neurosci., 12, 1-10. 11. Aeberg, D., Isgaard, J., Wallin, A., Johansson, J.-O., Adreasson, U., Blennow, K., Zetterberg, H., Aeberg, N. D. and Svensson, J. (2015) Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheime r’s Disease. J. Alzheimer’s Dis., 48, 637-646. 12. Huang, X., Xu, J., Shen, Y., Zhang, L., Xu, M., Chen, M. and Ren, J. (2019) Protein profiling of cerebrospinal fluid from patients undergoing vestibular schwannoma surgery and clinical significance. Biomed. Pharmacother., 116, 108985. 13. Wasik, N., Sokol, B., Holysz, M., Manko, W., Juszkat, R., Jagodzinski, P. P. and Jankowski, R. (2017) Clusterin, a New Cerebrospinal Fluid Biomarker in Severe SubarachnoidHemorrhage: A Pilot Study. World Neurosurg., 107, 424-428. 14. Jongbloed, W., Dijk, K. D. Van, Mulder, S. D. and Berg, W. D. J. Van De (2015) Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer’s Disease. J. Alzheimer’s Dis., 46, 1103-1110. 15. Morales, D., Hechavarria, R., Wojna, V. and Acevedo, S. F. (2013) YWHAE / 14-3-3ε: a potential novel genetic risk factor and CSF biomarker forHIV neurocognitive impairment. J. Neurovirol, 19, 471-478. 16. Morales, D., Skoulakis, E. C. M. and Acevedo, S. F. (2012) 14-3-3s are potential biomarkers forHIV-related neurodegeneration. J. Neurovirol, 18, 341-353. 17. Lubieniecka, J. M., Streijger, F., Lee, J. H. T., Stoynov, N., Liu, J., Mottus, R., Pfeifer, T., Kwon, B. K., Coorssen, J. R., Foster, L. J., et al. (2011) Biomarkers for Severity of Spinal Cord Injury in the Cerebrospinal Fluid of Rats. PLoS One, 6, e19247. 18. Martinez-Yelamos, A., Saiz, A., Sanchez-Valle, R., Casado, V., Ramon, J. M., Graus, F., Arbizu, T. and In (2001) 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology, 57, 722-725. 19. Vuletic, S., Kennedy, H., Albers, J. J., Killestein, J., Vrenken, H., Luetjohann, D. and Teunissen, C. E. (2014) Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables. Mult. Scler. Relat. Disord., 3, 533-541. 20. Ranganathan, S., Williams, E., Ganchev, P., Gopalakrishnan, V., Urbinelli, L., Newhall, K., Cudkowicz, M. E., Jr, R. H. B. and Bowser, R. (2005) Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem, 95, 1461-1471. 21. Vuletic, S., Peskind, E. R., Marcovina, S. M., Quinn, J. F., Cheung, M. C., Kennedy, H., Kaye, J. A., Jin, L. and Albers, J. J. (2005) Reduced CSF PLTP Activity in Alzheimer’s Disease and Other Neurologic Diseases; PLTP Induces ApoE Secretion in PrimaryHuman Astrocytes In Vitro. J. Neurosci. Res., 80, 406-413. 22. Batista Munoz, A., Hadley, S., Sanz, M. I., Quijano, T. A. and Camprubi, M. (2019) Role of beta-2-microglobulin as a biomarker in very preterm and extremely preterm infants with CNS inflammation. PLoS One. 23. Svatonova, J., Bolecka, K., Adam, P. and Lanska, V. (2014) Beta2-Microglobulin as a Diagnostic Marker in Cerebrospinal Fluid: A Follow-Up Study. Dis. Markers, 2014, 1-6. 24. Tsuji-Akimoto, S., Yabe, I., Niino, M., Kikuchi, S. and Sasaki, H. (2009) Cystatin C in cerebrospinal fluid as a biomarker of ALS. Neurosci. Lett., 452, 52-55. 25. Ren, Y., Zhu, W., Cui, F., Yang, F., Chen, Z., Ling, L. andHuang, X. (2015) Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Int J Clin Exp Pathol, 8, 5419-5426. 26. Vafadar-IIsfahani, B., Ball, G., Coveney, C., Lemetre, C., Boocock, D., Minthonc, L., Hanssonc, O., Milesa, A. K., Janciauskienee, S. M., Wardend, D., et al. (2012) Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer’s Disease in Cerebrospinal Fluid. J. Alzheimer’s Dis., 28, 625-636.27. Mo, F., Ma, X., Liu, X., Zhou, R., Zhao, Y. and Zhou, H. (2019) Altered CSF Proteomic Profiling of Paediatric Acute Lymphocytic Leukemia Patients with CNS Infiltration. J. Oncol., 2019, 1-8. 28. Sathe, G., Na, C. H., Renuse, S., Madugundu, A. K., Moghekar, A. and Pandey, A. (2018) Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer’s disease. Proteomics Clin Appl, 13, e1800105. 29. Dayon, L., Galindo, A. N., Wojcik, J., Cominetti, O., Corthesy, J., Oikonomidi, A., Henry, H., Kussmann, M., Migliavacca, E., Bowman, G. L., et al. (2018) Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimers. Res. Ther., 10, 1-12. 30. Chen, C., Xiao, D., Zhou, W. and Shi, Q. (2014) Global Protein Differential Expression Profiling of Cerebrospinal Fluid Samples Pooled from Chinese Sporadic CJD and non-CJD Patients. Mol Neurobiol, 49, 290-302. 31. Schultz, K., Nilsson, K., Nielsen, J. E., Lindquist, S. G., Hjermind, L. E. and Andersen, B. B. (2010) Transthyretin as a potential CSF biomarker for Alzheimer’s disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. Eur. J. Neurol., 17, 456-460. 32. Quaranta, A., Karlsson, I., Ndreu, L., Marini, F., Ingelsson, M. and Thorsen, G. (2019) Glycosylation profiling of selected proteins in cerebrospinal fluid from Alzheimer’s disease andHealthy subjects. Anal. Methods, 11, 3331-3340. 33. Yan, X., Mai, L., Lin, C., He, W. and Yin, G. (2017) CSF-Based Analysis for Identification of Potential Serum Biomarkers of Neural Tube Defects. Neurosci. Bull., 33, 436-444. 34. Orchard, P. J., Nascene, D. R., Gupta, A., Taisto, M. E., Higgins, L., Markowski, T. W. and Lund, T. C. (2019) Cerebral adrenoleukodystrophy is associated with loss of tolerance to profilin. Eur J Immunol, 49, 947-953. 35. McLimans, K. E. and Willette, A. A. (2016) Novel CSF Biomarker of Metabolic Dysfunction Predicts AD-like Associations across the Alzheimer’s Spectrum. FASEB J., 30, lb304-lb304. 36. McLimans, K. E. and Willette, A. A. (2017) Autotaxin is Related to Metabolic Dysfunction and Predicts Alzheimer’s Disease Outcomes. J. Alzheimer’s Dis., 56, 403-413. 37. Heywood, W. E., Galimberti, D., Bliss, E., Sirka, E., Paterson, R. W., Magdalinou, N. K., Carecchio, M., Reid, E., Heslegrave, A., Fenoglio, C., et al. (2015) Identification of novel CSF biomarkers for neurodegeneration and their validation by aHigh-throughput multiplexed targeted proteomic assay. Mol. Neurodegener., 10, 1-16. 38. N, K., P, A., M, K., P, S. and K., K. (2015) Spinal Fluid Lactate Dehydrogenase Level Differentiates between Structural and Metabolic Etiologies of Altered Mental Status in Children. Iran J Child Neurol, 9, 31-36. 39. Parkkila, A.-K., Parkkila, S., Reunanen, M., Niemela, O., Tuisku, S., Rautakorpi, I. and Rajaniemi, H. (1997) Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker. Eur. J. Clin. Invest., 27, 392-397. 40. Guo, Z., Zhang, Y., Zou, L., Wang, D., Shao, C. and Wang, Y. (2015) A Proteomic Analysis of Individual and Gender Variations in NormalHuman Urine and Cerebrospinal Fluid Using iTRAQ Quantification. PLoS One, 10, 1-17. 41. Lewis, S. B., Wolper, R., Chi, Y., Miralia, L., Wang, Y., Yang, C. and Shaw, G. (2010) Identification and Preliminary Characterization of Ubiquitin C Termin alHydrolase 1 (UCHL1) as a Biomarker of Neuronal Loss in Aneurysmal SubarachnoidHemorrhage. J. Neurosci. Res.,88, 1475-1484. 42. Futakawa, S., Nara, K., Miyajima, M., Kuno, A. and Ito, H. (2012) A unique N-glycan onHuman transferrin in CSF: a possible biomarker for iNPH. Neurobiol. Aging, 33, 1807-1815. 43. Dobson, R., Topping, J., Davis, A., Thompson, E. and Giovannoni, G. (2013) Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol. Scand., 10. 1111 / ane. 12119. 44. Streijger, F., Skinnider, M. A., Rogalski, J. C., Balshaw, R., Shannon, C. P., Prudova, A., Belanger, L., Ritchie, L., Tsang, A., Christie, S., et al. (2017) A Targeted Proteomics Analysis of Cerebrospinal Fluid after AcuteHuman Spinal Cord Injury. J. Neurotrauma, 34, 2054-2068. 45. Albayar, A. A., Roche, A., Swiatkowski, P., Antar, S., Ouda, N., Emara, E., Smith, D. H., Ozturk, A. K. and Awad, B. I. (2019) Biomarkers in Spinal Cord Injury: Prognostic Insights and Future Potentials. Front. Neurol., 10, 1-14. 46. Kessler, H., Pajonk, F., Meisser, P., Hoffmann, K., Supprian, T., Herrmann, W., Obeid, R., Multhaup, G., Falkai, P. and Bayer, T. A. (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer’s disease. J Neural Transm, 113, 1763-1769. 47. Kallianpur, A. R., Gittleman, H., Letendre, S., Ellis, R., Bush, W. S. andHeaton, R. (2019) Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults withHIV Infection. Mol. Neurobiol., 56, 3808-3818. 48. Saito, Y. (2017) DJ-1 as a Biomarker of Parkinson’s Disease. In 1037. pp. 149-171. 49. Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-agnaf, O. and Calabresi, P. (2013) Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Publ. Gr.,9, 131-140. 50. Hong, Z., Shi, A. M., Chung, A. K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) DJ-1 and a-synuclein inHuman cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain A J. Neurol., 133, 713-726. 51. Blennow, K., Wallin, A., Andreasson, U., Bjerke, M. and Zetterberg, H. (2011) Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer’s Disease. J. Alzheimer’s Dis., 27, 665-676. 52. Duits, F. H., Hernandez-guillamon, M., Montaner, J., Goos, J. D. C., Monta, A., Wattjes, M. P., Barkhof, F., Scheltens, P. and Teunissen, C. E. (2015) Matrix Metalloproteinases in Alzheimer’s Disease and Concurrent Cerebral Microbleeds. J. Alzheimer’s Dis., 48, 711-720. 53. Singh, A., Beveridge, A. J. and Singh, N. (2011) Decreased CSF Transferrin in sCJD: A Potential Pre-Mortem Diagnostic Test for Prion Disorders. PLoS One, 6, e16804. 54. Ho, J. K., Lee, S. K., Yoo, Y. C., Park, N. H., Park, D. B., Yoo, J. S., An, H. J., Park, Y. M. and Gi, K. C. (2012) Proteome analysis ofHuman cerebrospinal fluid as a diagnostic biomarker in patients with meningioma. Med Sci Monit, 18, 450-460. 55. Martins-De-Souza, D., Wobrock, T., Zerr, I., Schmitt, A., Gawinecka, J., Schneider-axmann, T., Falkai, P. and Turck, C. W. (2010) Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fl uid of schizophrenia patients. World J. Biol. Psychiatry, 11, 719-728. 56. Perrin, R. J., Craig-schapiro, R., Malone, J. P., Shah, A. R., Gilmore, P., Quinn, J. F., Kaye, J. A., Morris, J. C., Holtzman, D. M. and Reid, R. (2011) Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer’s Disease. PLoS One, 6, e16032. 57. Nielsen, H. M., Minthon, L. and Londos, E. (2013) Plasma and CSF serpins in Alzheimer’s disease and dementia with Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Am. Acad. Neurol., 69, 1569-1579. 58. Dzieciatkowska, M., Qi, G., You, J., Bemis, K. G., Sahm, H., Lederman, H. M., Crawford, T. O., Gelbert, L. M., Rothblum-oviatt, C. and Wang, M. (2011) Proteomic Characterization of Cerebrospinal Fluid from Ataxia-Telangiectasia (A-T) Patients Using a LC / MS-Based Label-Free Protein Quantification Technology. Int. J. Proteomics, 2011, 1-13. 59. Poljak, A., Hill, M., Hall, R. J., Maclullich, A. M., Raftery, M. J., Tai, J., Yan, S. and Caplan, G. A. (2014) Quantitative proteomics of delirium cerebrospinal fl uid. Transl. Psychiatry, 4, 1-10. 60. Benetello, P., Furlanut, M., Zara, G., Massimo, B. and EidHassan (1993) Plasma Levels of Levodopa and Its Main Metabolites in Parkinsonian Patients after Conventional and Controlled-Release Levodopa-Carbidopa Associations. Eur. Neurol., 33, 69-73. 61. Das, I., Krzyzosiak, A., Schneider, K., Wrabetz, L., Antonio, M. D., Barry, N., Sigurdardottir, A. and Bertolotti, A. (2015) Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. 348, 239-243. 62. Evans, W. E., Hutson, P. R., Stewart, C. D., Cairnes, D. A., Bowman, P. W., Rivera, G. and Crom, W. R. (1983) Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin. Pharmacol. Ther., 33, 301-307. 63. Golden, R. N., Rudorfer, M. V, Sherer, M. A., Linnoila, M. and Potter, W. Z. (1988) Bupropion in Depression. Arch Gen Psychiatry, 45, 139-143. 64. Onash, A., Tanzeen, A., Isgro, F., Boening, D. and Strobel, G. (2000) Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18H after infusion. Eur J Clin Pharmacol.,55, 755-759. 65. Rizzo, N., Padoin, C., Palombo, S., Schermann, J.-M. and Girre, C. (1996) Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Eur J Clin Pharmacol., 49, 491-495. 66. Seri, I., Tulassay, T., Kiszel, J. and Machay, T. (1984) Cardiovascular response to dopamine inHypotensive preterm neonates. 67. Jackson, D. V, Sethi, V. S., Spurr, C. L. and Mcwhorter, J. M. (1981) Pharmacokinetics of Vincristine in the Cerebrospinal Fluid ofHumans1. 68. Jackson, D. V, Sethi, V. S., Long, T. R., Muss, H. B. and Spurr, C. L. (1984) Pharmacokinetics of vindesine bolus and infusion. Cancer Chemother. Pharmacol., 0, 114-119.

Claims

1. (a) an epithelium comprising a tight epithelial barrier; and / or (b) a choroid plexus organoid comprising one or more cysts surrounded by epithelium.

2. The choroid plexus organoid of claim 1, wherein the epithelium is TTR+, MRP1+, Aqp1+ and / or ZO1+.

3. The choroid plexus organoid of claim 2, wherein the TTR, Aqp1 and / or ZO1 are accumulated on the apical side of the epithelium.

4. The choroid plexus organoid of claim 2, wherein the MRP1 is accumulated on the apical and basal sides of the epithelium.

5. The choroid plexus organoid of any one of claims 1 to 4, wherein the epithelium comprises apical microvilli and, optionally, primary cilia.

6. The choroid plexus organoid of any one of claims 1 to 5, further comprising (c) interstitial cells.

7. The choroid plexus organoid according to any one of claims 1 to 6, which is a lateral ventricular choroid plexus organoid.

8. The choroid plexus organoid of any one of claims 1 to 7, wherein the one or more cysts are filled with a liquid, and preferably the liquid contains one or more proteins selected from the group consisting of transthyretin (TTR), clusterin (CLU), apolipoprotein E (APOE), apolipoprotein A4 (APOA4) and lumican (LUM).

9. Use of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator to generate choroid plexus organoids, the choroid plexus organoids comprising: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by the epithelium.

10. A method for producing choroid plexus organoids, comprising generating a neuroepithelial cell population from a stem cell population and culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator.

11. The method of claim 10, wherein culturing the neuroepithelial cell population in the presence of a WNT pathway activator and a BMP signaling pathway activator is initiated about 8 to 12 days after initiating culture of the stem cell population.

12. 1. A method for producing choroid plexus organoids, comprising: (a) generating an embryoid body population by culturing a stem cell population; (b) culturing said population of embryoid bodies under conditions suitable for neural induction; (c) embedding the product of step (b) in a three-dimensional matrix, preferably an extracellular matrix (ECM); (d) culturing the product of step (c) in the presence of a WNT pathway activator and a bone morphogenetic protein (BMP) signaling pathway activator, preferably beginning about 8-12 days after the initiation of step (a). The method includes:

13. 13. The method of claim 12, wherein the culturing in step (d) comprises agitation.

14. The use or method according to any one of claims 9 to 13, wherein the WNT pathway activator is selected from the group consisting of CHIR99021, Wnt1, Wnt2, Wnt3, Wnt3a, Wnt8a, Wnt8b, Wnt10a, Wnt10b, BML-284, 6-bromoindirubin-3'-oxime (BIO), WAY-316606, IQ1, QS11, SB-216763, LY2090314, DCA, 2-amino-4-[3,4-(methylenedioxy)benzyl-amino]-6-(3-methoxyphenyl)pyrimidine and lithium, preferably, the WNT pathway activator is CHIR99021.

15. The use or method according to any one of claims 9 to 14, wherein the BMP signalling pathway activator is selected from the group consisting of Bmp4, Bmp2, Bmp3, Bmp5, Bmp6, Bmp7, Bmp8a, Bmp8b, Bmp10, Bmp11, Bmp15, isoliquiritigenin, 4'-hydroxychalcone, apigenin, diosmetin and ventromorphins (e.g. SJ000291942, SJ000063181 and / or SJ00037178), preferably the BMP signalling pathway activator is Bmp4.

16. Use of the choroid plexus organoid according to any one of claims 1 to 8 for drug discovery screening or drug toxicity assays.

17. 17. The use according to claim 16, wherein the use is for testing the ability of a candidate drug to cross the blood-cerebrospinal fluid (CSF) barrier.

18. A method for testing the ability of a candidate agent to cross the blood-cerebrospinal fluid (CSF) barrier, comprising contacting a choroid plexus organoid according to any one of claims 1 to 8 with the candidate agent and determining whether the candidate agent crosses the epithelium.